[go: up one dir, main page]

MC2146A1 - Immunoglogulines chimeriques specifiques de la proteine p55 tac du recepteur de l'il-2 - Google Patents

Immunoglogulines chimeriques specifiques de la proteine p55 tac du recepteur de l'il-2

Info

Publication number
MC2146A1
MC2146A1 MC@@@@D MC2146D MC2146A1 MC 2146 A1 MC2146 A1 MC 2146A1 MC 2146 D MC2146 D MC 2146D MC 2146 A1 MC2146 A1 MC 2146A1
Authority
MC
Monaco
Prior art keywords
human
receptor
cdr
tac
protein
Prior art date
Application number
MC@@@@D
Other languages
English (en)
French (fr)
Inventor
Queen Cary
Edwin Selick Harold
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26966505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MC2146(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Publication of MC2146A1 publication Critical patent/MC2146A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MC@@@@D 1988-12-28 1989-12-28 Immunoglogulines chimeriques specifiques de la proteine p55 tac du recepteur de l'il-2 MC2146A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29097588A 1988-12-28 1988-12-28
US31025289A 1989-02-13 1989-02-13
PCT/US1989/005857 WO1990007861A1 (en) 1988-12-28 1989-12-28 CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR

Publications (1)

Publication Number Publication Date
MC2146A1 true MC2146A1 (fr) 1992-02-18

Family

ID=26966505

Family Applications (1)

Application Number Title Priority Date Filing Date
MC@@@@D MC2146A1 (fr) 1988-12-28 1989-12-28 Immunoglogulines chimeriques specifiques de la proteine p55 tac du recepteur de l'il-2

Country Status (31)

Country Link
EP (6) EP1491556B1 (de)
JP (6) JP2828340B2 (de)
KR (1) KR0178385B1 (de)
CN (1) CN1057013C (de)
AT (2) ATE133452T1 (de)
AU (1) AU647383B2 (de)
BG (1) BG61095B2 (de)
CA (2) CA2006865C (de)
CZ (1) CZ418691A3 (de)
DD (1) DD296964A5 (de)
DE (14) DE122007000037I1 (de)
DK (2) DK119191D0 (de)
ES (5) ES2440825T3 (de)
FI (1) FI108797B (de)
FR (1) FR14C0070I1 (de)
HR (1) HRP920500B1 (de)
HU (1) HU211174A9 (de)
IE (1) IE20000331A1 (de)
IL (2) IL162181A (de)
LU (8) LU90411I2 (de)
MC (1) MC2146A1 (de)
NL (8) NL990020I2 (de)
NO (9) NO310473B1 (de)
NZ (2) NZ314793A (de)
PT (1) PT92758B (de)
RU (1) RU2126046C1 (de)
SG (1) SG78258A1 (de)
SI (1) SI8912489B (de)
WO (1) WO1990007861A1 (de)
YU (1) YU48700B (de)
ZA (1) ZA899956B (de)

Families Citing this family (1049)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800815A (en) * 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
US5851526A (en) * 1985-04-19 1998-12-22 Ludwig Institute For Cancer Research Methods of treating colon cancer utilizing tumor-specific antibodies
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7247453B1 (en) * 1988-12-30 2007-07-24 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein C
DE3900534A1 (de) * 1989-01-10 1990-07-12 Boehringer Mannheim Gmbh Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
DE69027121T3 (de) 1989-08-07 2001-08-30 Peptech Ltd., Dee Why Bindeligande für tumornekrosisfaktor
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GR1001050B (el) * 1990-01-09 1993-04-28 Protein Design Labs Inc Νεος il-2 υποδοχευς ιδιαζοντων ανθρωπινων ανοσοσφαιρινων.
HUT60768A (en) 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
US5858725A (en) * 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
US5994510A (en) * 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
ES2204890T3 (es) * 1991-03-06 2004-05-01 Merck Patent Gmbh Anticuerpos monoclonales humanizados.
IL101147A (en) * 1991-03-07 2004-06-20 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
WO1992017505A1 (en) * 1991-04-05 1992-10-15 Board Of Regents Of The University Of Washington Monoclonal antibodies to stem cell factor receptors
HU218140B (hu) * 1991-04-25 2000-06-28 Chugai Seiyaku Kabushiki Kaisha Humán interleukin-6-receptorral szembeni átalakított humán antitest
DE69233482T2 (de) * 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
CA2103059C (en) * 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115010D0 (en) * 1991-07-11 1991-08-28 Wellcome Found Antibody
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5709860A (en) * 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US5756096A (en) * 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
JP3939746B2 (ja) * 1991-07-25 2007-07-04 バイオジェン・アイデック・インコーポレイテッド 細胞毒性ｔ−リンパ球応答の誘導
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US6329509B1 (en) 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
US6685939B2 (en) 1991-08-14 2004-02-03 Genentech, Inc. Method of preventing the onset of allergic disorders
DK0528767T3 (da) * 1991-08-21 2000-04-17 Novartis Ag antistofderivater
GB9120467D0 (en) * 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
JP3024311B2 (ja) * 1991-10-03 2000-03-21 味の素株式会社 Ｉｌ−２受容体重鎖に結合するポリペプチド
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5817310A (en) * 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP1291360A1 (de) * 1991-12-13 2003-03-12 Xoma Corporation Verfahren und Materialien zur Herstellung von modifizierten Antikörper Variablen Domänen und deren therapeutischen Verwendung
US5777085A (en) * 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
DE69333807T2 (de) * 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
GB9203459D0 (en) * 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5387676A (en) * 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US6033667A (en) * 1992-05-05 2000-03-07 Cytel Corporation Method for detecting the presence of P-selectin
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) * 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5958708A (en) * 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
GB9223377D0 (en) * 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5648267A (en) * 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
EP0669986B1 (de) * 1992-11-13 2003-04-09 Idec Pharmaceuticals Corporation Konsensus-kozak-sequenzen zur säugetier-exprimierung
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5804187A (en) * 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
SG44845A1 (en) 1993-01-12 1997-12-19 Biogen Inc Recombitant anti-vla4 antibody molecules
US5951983A (en) * 1993-03-05 1999-09-14 Universite Catholique De Louvain Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
US5730979A (en) * 1993-03-05 1998-03-24 Universite Catholique Delouvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
FI955261A7 (fi) * 1993-05-04 1996-01-03 Cytel Corp P-selektiinin vasta-aineita ja niiden käyttö
DE69434812D1 (de) * 1993-05-28 2006-09-14 Scripps Research Inst Methoden für inhibition der cd14-abhängigen zellaktivierung
TW458985B (en) * 1993-05-31 2001-10-11 Chugai Pharmaceutical Co Ltd Reconstructed human antibody against human interleukin-6
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
RU2162711C2 (ru) * 1993-09-07 2001-02-10 Смитклайн Бичам Корпорейшн Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
HU222041B1 (hu) * 1993-09-07 2003-04-28 Smithkline Beecham Corporation Az IL4 által kőzvetített rendellenességek kezelésére használható rekombináns 1L4 antitestek, eljárás ezek előállítására, alkalmazására és az őket tartalmazó gyógyszerkészítmények
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
AU7949394A (en) 1993-11-19 1995-06-06 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human medulloblastomatous cell
WO1995015181A1 (en) * 1993-11-30 1995-06-08 Protein Design Labs, Inc. Reperfusion therapy using antibodies to l-selectin
GB9325182D0 (en) * 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
NZ279730A (en) * 1994-01-25 1998-04-27 Athena Neurosciences Inc Humanized antibodies against leukocyte adhesion molecule vla-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
CA2186455A1 (en) 1994-03-29 1995-10-05 Raymond John Owens Antibodies against e-selectin
US5635597A (en) * 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
USRE39548E1 (en) * 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US6048972A (en) * 1994-07-13 2000-04-11 Chugai Pharmaceutical Co., Ltd. Recombinant materials for producing humanized anti-IL-8 antibodies
DE4425115A1 (de) * 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
EP0696455A1 (de) * 1994-08-11 1996-02-14 Cellena (Cell Engineering) A.G. Transferrin Zusammensetzungen zur Erleichterung der Nebenwirkungen der cytotoxischen Medikamente
US8771694B2 (en) * 1994-08-12 2014-07-08 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
US5707621A (en) * 1994-08-31 1998-01-13 Chugai Pharmaceutical Co., Ltd. Supression of nephritis-induced protein excretion by anti-IL-8
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
AU6171196A (en) * 1995-06-07 1996-12-30 Sloan-Kettering Institute For Cancer Research Therapeutic uses of ta99
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
GB9600660D0 (en) 1996-01-12 1996-03-13 Ciba Geigy Ag Protein
WO1997033617A1 (en) * 1996-03-13 1997-09-18 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
US5882644A (en) * 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US6713305B1 (en) 1996-04-29 2004-03-30 Novartis Ag Metastasis-associated antigen and antibodies thereto
WO1997046589A2 (en) 1996-06-07 1997-12-11 Neorx Corporation Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
US6534311B2 (en) 1996-07-24 2003-03-18 Novartis Ag Drosophila melanogaster p70S6 kinase
US6833255B1 (en) 1996-07-24 2004-12-21 Novartis, Ag Drosophila melanogaster p70 S6 kinase
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP1642908A2 (de) * 1996-09-02 2006-04-05 Okumura, Ko Fas-liganden abstammende apoptosis induzierende Region
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
CZ106299A3 (cs) 1996-09-26 1999-08-11 Chugai Seiyaku Kabushiki Kaisha Protilátky proti proteinu příbuznému s lidským parathyroidálním hormonem
UA76934C2 (en) 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
US7883872B2 (en) 1996-10-10 2011-02-08 Dyadic International (Usa), Inc. Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
US20020160005A1 (en) 1996-11-15 2002-10-31 Trustees Of Tufts College Human neutralizing antibodies against hemolytic urmec syndrome
US7910096B2 (en) 1996-11-15 2011-03-22 Trustees Of Tufts College Human neutralizing antibodies against hemolytic uremic syndrome
US6017729A (en) 1996-12-23 2000-01-25 Immunex Corporation Receptor activator of NF-κB
US6262238B1 (en) * 1997-01-14 2001-07-17 Roche Diagnostic, Gmbh Process for modifying the stability of antibodies
US6590079B2 (en) 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US6596850B1 (en) 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
AU736287B2 (en) * 1997-03-21 2001-07-26 Sankyo Company Limited Humanized anti-human Fas antibody
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
SI1325932T1 (de) 1997-04-07 2005-08-31 Genentech Inc
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
ATE361099T1 (de) 1997-05-15 2007-05-15 Chugai Pharmaceutical Co Ltd Heilmittel für kachexie
EP0983303B1 (de) * 1997-05-21 2006-03-08 Biovation Limited Verfahren zur herstellung von nicht-immunogenen proteinen
EP1019082B2 (de) 1997-10-02 2008-06-04 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Verwendung eines kolonie-stimulierenden faktors (csf) zum verstärken des kollateralen wachstums von kollateralen arterien und / oder anderer arterien aus bestehenden arteriolären verbindungen
AU750453B2 (en) * 1997-10-03 2002-07-18 Chugai Seiyaku Kabushiki Kaisha Natural human antibody
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
EP1745799B1 (de) 1998-03-04 2015-09-02 The Trustees of The University of Pennsylvania Zusammensetzungen und Verfahren zur Behandlung von Tumoren
SK14812000A3 (sk) 1998-04-03 2001-08-06 Chugai Seiyaku Kabushiki Kaisha Chimérny reťazec protilátky, chimérna protilátka, v oblasť, humanizovaný reťazec protilátky, humanizovaná protilátka, dna, expresný vektor, hostiteľ, spôsob prípravy a liečivo
WO2000009160A1 (en) 1998-08-11 2000-02-24 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
JP4689781B2 (ja) * 1998-09-03 2011-05-25 独立行政法人科学技術振興機構 アミノ酸輸送蛋白及びその遺伝子
SK287601B6 (sk) 1998-09-14 2011-03-04 Board Of Regents, The University Of Texas System Použitie protilátky alebo jej fragmentu viažuceho antigén na výrobu farmaceutickej kompozície na liečenie mnohonásobného myelómu a na inhibíciu resorpcie kostí
KR100618495B1 (ko) 1998-10-06 2006-08-31 마크 아론 에말파브 섬유상의 진균성 숙주 영역에서의 형질전환 시스템:크리소스포륨속에서
EP1939215A1 (de) 1998-10-22 2008-07-02 The University of Montana Omp85-Proteien von Neisseria Gonorrhoeae und Neisseria Meningitidis, Zusammensetzungen damit und ihre Verwendungsverfahren
CN1679934B (zh) 1998-11-09 2012-09-05 生物基因Idec公司 使用抗cd20嵌合抗体治疗循环肿瘤细胞相关的血液恶性肿瘤
GB9825632D0 (en) 1998-11-23 1999-01-13 Novartis Ag Organic compounds
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
EP1119368A2 (de) 1999-03-03 2001-08-01 Biogen, Inc. Verfahren zür modulierung des fettstoffwechsels und lagerung
GB9906380D0 (en) * 1999-03-19 1999-05-12 Melvin William T Monoclonal antibodies specific for cypibi
CA2370814C (en) 1999-04-22 2010-07-06 Biogen, Inc. Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
IT1306704B1 (it) * 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
WO2000072881A1 (en) 1999-06-01 2000-12-07 Biogen, Inc. A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
US6531580B1 (en) 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
TWI255718B (en) 1999-07-02 2006-06-01 Chugai Pharmaceutical Co Ltd Ameliorative agent for low vasopressin concentration
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
JP4689124B2 (ja) * 1999-09-30 2011-05-25 協和発酵キリン株式会社 ガングリオシドｇｄ３に対するヒト型相補性決定領域移植抗体およびガングリオシドｇｄ３に対する抗体の誘導体
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
AU784634B2 (en) 1999-11-30 2006-05-18 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
ES2335643T3 (es) 1999-12-16 2010-03-31 Biogen Idec Ma Inc. Metodos de tratamiento de lesion isquemica o hemorragica del sistema nervioso central usando antagonistas anti-integrinas alfa 4.
ES2349348T3 (es) 2000-01-27 2010-12-30 Medimmune, Llc Anticuerpos neutralizantes de rsv de ultra alta afinidad.
AU2001240020B9 (en) 2000-03-01 2008-12-04 Medimmune, Llc High potency recombinant antibodies and method for producing them
ATE373719T1 (de) * 2000-02-03 2007-10-15 Millennium Pharm Inc Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
CA2399387C (en) 2000-02-11 2015-11-03 Biogen, Inc. Heterologous polypeptide of the tnf family
SI1481992T1 (sl) 2000-02-24 2017-01-31 Washington University St. Louis Humanizirana protitelesa, ki vežejo amiloidni peptid beta
US6663863B2 (en) 2000-03-17 2003-12-16 Millennium Pharmaceuticals, Inc. Method of inhibiting stenosis and restenosis
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
JP4846169B2 (ja) 2000-04-28 2011-12-28 中外製薬株式会社 細胞増殖抑制剤
ES2316446T3 (es) 2000-04-29 2009-04-16 University Of Iowa Research Foundation Diagnostico y terapeutica para trastornos relacionados con la degeneracion macular.
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
WO2002028481A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6989247B2 (en) 2000-11-28 2006-01-24 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
AU2002315271B2 (en) * 2001-04-06 2006-08-03 University Of Bristol Use of CD25 binding molecules in steroid-resistant patients
US7358054B2 (en) 2001-04-13 2008-04-15 Biogen Idec Ma Inc. Antibodies to VLA-1
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
HUP0400030A3 (en) * 2001-05-18 2006-02-28 Boehringer Ingelheim Pharma Antibodies specific for cd44v6
US7541443B2 (en) * 2001-06-14 2009-06-02 Tolerrx, Inc. Anti-CD4 antibodies
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20030013081A1 (en) 2001-06-26 2003-01-16 Olson William C. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
JP4675512B2 (ja) * 2001-07-10 2011-04-27 三井化学株式会社 熱殺菌方法
CA2898314A1 (en) 2001-07-19 2003-07-31 Perian Therapeutics, Inc. Multimeric proteins and methods of making and using same
EP1420032B2 (de) † 2001-08-03 2015-12-16 Medical & Biological Laboratories Co., Ltd. ANTIKÖRPER, DER DAS GM1-GANGLIOSID-GEBUNDENE AMYLOID-b-PROTEIN ERKENNT, UND DNA, DIE FÜR DIESEN ANTIKÖRPER CODIERT
DK1944040T3 (da) 2001-08-17 2012-10-29 Univ Washington Analysefremgangsmåde for Alzheimers sygdom
LT1434871T (lt) 2001-09-20 2017-04-10 Immunex Corporation Heteromerinius polipeptidus ekspresuojančių ląstelių atranka
CA2461529A1 (en) 2001-09-25 2003-04-03 Immuno-Biological Laboratories Co., Ltd. Recombinant anti-osteopontin antibody and use thereof
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
US20030190705A1 (en) * 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
JP4304073B2 (ja) * 2001-11-12 2009-07-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 改変された抗ＴＮＦα抗体
EP1944043A1 (de) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Nukleinsäure- und Aminosäuresequenzen von Affen-Adenoviren, hergeleitete Vektoren und Verwendungsverfahren.
PL209133B1 (pl) 2001-11-21 2011-07-29 Univ Pennsylvania Rekombinowany adenowirus, obejmująca go izolowana komórka gospodarza, oraz kompozycja i zastosowanie
WO2003048083A2 (en) 2001-11-30 2003-06-12 Biogen Idec Ma Inc. Antibodies against monocyte chemotactic proteins
ATE550352T1 (de) * 2001-12-03 2012-04-15 Alexion Pharma Inc Verfahren zur herstellung von hybridantikörper
US7393648B2 (en) 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
CN100522999C (zh) * 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
IL163655A0 (en) * 2002-02-22 2005-12-18 Protein Design Labs Inc Anti-ccr5 antibody
WO2003072040A2 (en) 2002-02-25 2003-09-04 Elan Pharmaceuticals, Inc. Administration of agents for the treatment of inflammation
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
BRPI0308585B8 (pt) 2002-03-13 2021-05-25 Biogen Idec Inc anticorpo isolado ou fragmento de ligação a antígeno do mesmo que se liga à alfavbeta6, composição, método de detecção in vitro de alfavbeta6 e construção de dna
ES2358505T3 (es) 2002-03-20 2011-05-11 Ucb Pharma, S.A. Métodos para analizar isómeros de disulfuro de anticuerpos.
CA2480059C (en) * 2002-03-22 2015-11-24 Amrad Operations Pty. Ltd. Monoclonal antibody against interleukin-13 receptor alpha 1 (il-13r.alpha.1)
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
CA2485969A1 (en) 2002-05-14 2003-11-27 Martek Biosciences Corporation Carotene synthase gene and uses therefor
US7601817B2 (en) 2002-05-28 2009-10-13 Ucb Pharma S.A. Antibody peg positional isomers, compositions comprising same, and use thereof
CA2487932A1 (en) * 2002-05-30 2003-12-11 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
GB0213745D0 (en) 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
WO2003106485A1 (en) 2002-06-14 2003-12-24 Monier Tadros Method for the production of protamine
CA2490804C (en) 2002-06-28 2016-12-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
US9535076B2 (en) 2002-09-12 2017-01-03 The Regents Of The University Of California Methods and compositions for eliciting an amyloid-selective immune response
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
NZ540555A (en) 2002-11-15 2008-04-30 Genmab As Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
EP2363410B1 (de) 2002-11-27 2017-10-11 Minerva Biotechnologies Corporation MUC1-Isoformen
WO2004056312A2 (en) 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
WO2004065417A2 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
JP2007521249A (ja) 2003-01-24 2007-08-02 エラン ファーマシューティカルズ，インコーポレイテッド 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療
EP1460088A1 (de) 2003-03-21 2004-09-22 Biotest AG Humanisierter Antikörper gegen CD4 mit immunsuppressiven Merkmalen
US7321065B2 (en) 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
DK1631312T3 (da) 2003-04-23 2009-01-19 Medarex Inc Sammensætning og fremstillingsmåde til behandling af inflammatorisk tarmsygdom
CA2523142A1 (en) 2003-04-23 2004-11-04 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
DK2361928T3 (en) 2003-05-19 2017-07-03 Prothena Biosciences Ltd Truncated fragments of alpha synuclein in Lewy body disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
EP2239271A1 (de) 2003-06-13 2010-10-13 Biogen Idec MA Inc. Aglycosyl Anti-CD154 (CD40 Ligand)-Antikörper und ihre Verwendungen
US8153410B2 (en) 2003-07-07 2012-04-10 Fox Chase Cancer Center Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
US20060162014A1 (en) 2003-07-07 2006-07-20 Jaffe Eileen K Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
EP3594228A1 (de) 2003-07-08 2020-01-15 Genentech, Inc. Heterologe il-17a/f-polypeptide und deren therapeutische verwendungen
EP2341067A1 (de) 2003-07-18 2011-07-06 Amgen, Inc Spezifische Bindemittel zu Hepatozytenwachstumsfaktor
US7834155B2 (en) 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
EP1693385A4 (de) 2003-11-11 2009-11-04 Chugai Pharmaceutical Co Ltd Humanisierter anti-cd47-antikörper
AU2004290059A1 (en) 2003-11-12 2005-05-26 Albert Einstein College Of Medicine Of Yeshiva University Novel sequences encoding hepatitis C virus glycoproteins
WO2005054295A2 (en) 2003-12-05 2005-06-16 Multimmune Gmbh Therapeutic and diagnostic anti-hsp 70 antibodies
AU2004297265A1 (en) 2003-12-08 2005-06-23 Eisai, Inc. Antibodies that specifically bind PMS2
CA2549800A1 (en) 2003-12-15 2005-06-30 Alexion Pharmaceuticals, Inc. Novel anti-dc-sign antibodies
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
BRPI0506726B8 (pt) 2004-01-07 2021-05-25 Chiron Corp anticorpo monoclonal específico para m-csf e usos deste
WO2005068504A1 (ja) 2004-01-19 2005-07-28 Medical And Biological Laboratories Co., Ltd. 炎症性サイトカイン抑制剤
AU2005216013B2 (en) 2004-01-30 2010-11-11 Dana Farber Cancer Institute Method for determination and quantification of radiation or genotoxin exposure
PL1713503T3 (pl) 2004-02-10 2014-02-28 Univ Colorado Regents Hamowanie czynnika B, alternatywny szlak dopełniacza i związane z tym sposoby
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
US20050232919A1 (en) 2004-02-12 2005-10-20 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
EP1717250A4 (de) 2004-02-20 2008-10-01 Immuno Biological Lab Co Ltd Monoklonaler antikörper und dessen verwendung
NZ549787A (en) 2004-03-12 2010-05-28 Vasgene Therapeutics Inc Antibodies binding to EphB4 for inhibiting angiogenesis and tumor growth
US7625549B2 (en) 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
EP1729804A2 (de) 2004-03-19 2006-12-13 Amgen Inc. Verringerung des risikos von humanen und anti-humanen antikörpern durch v-genmanipulation
BRPI0508761A (pt) 2004-03-31 2007-08-14 Genentech Inc anticorpo humanizado, composição que compreende um anticorpo humanizado, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo humanizado, método de tratamento de disfunção tgf-beta, método de detecção de tgf-beta, artigo industrializado e método de tratamento de cáncer
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
EP1734996B1 (de) 2004-04-02 2013-05-22 The Regents of The University of California Verfahren und zusammensetzungen für die behandlung und vorbeugung von mit alpha v beta 5-integrin assoziierten krankheiten
EP1761784B1 (de) 2004-05-24 2016-10-26 Universität Zu Köln Identifizierung des ergothionein-transporters und therapeutische verwendungen davon
EP1602926A1 (de) 2004-06-04 2005-12-07 University of Geneva Neue Mittel und Verfahren zur Behandlung von Gehörverlust oder Tinnitus
RU2412202C2 (ru) 2004-06-21 2011-02-20 Медарекс, Инк. Антитела рецептора 1 интерферона альфа и их применение
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
BRPI0513798A (pt) 2004-07-26 2008-05-13 Biogen Idec Inc anticorpos anti-cd154
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
EA013752B1 (ru) 2004-08-09 2010-06-30 Элан Фармасьютикалз, Инк. Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
FI20041204A0 (fi) 2004-09-16 2004-09-16 Riikka Lund Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi
ATE497508T1 (de) 2004-10-01 2011-02-15 Max Planck Gesellschaft Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper
SI1810026T1 (en) 2004-10-06 2018-08-31 Mayo Foundation For Medical Education And Research B7-H1 and PD-1 in the treatment of renal cell carcinoma
SG156672A1 (en) 2004-10-22 2009-11-26 Amgen Inc Methods for refolding of recombinant antibodies
JP5173426B2 (ja) 2004-10-25 2013-04-03 メルク・シャープ・エンド・ドーム・コーポレイション 抗ａｄｄｌ抗体およびこの使用
WO2006055871A2 (en) 2004-11-19 2006-05-26 Biogen Idec Ma Inc. Treatment for multiple sclerosis
EP1838348B1 (de) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
CA2594356C (en) 2005-01-05 2018-07-17 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
MX2007008785A (es) 2005-01-27 2008-02-15 Childrens Hosp & Res Ct Oak Vacunas de vesicula basadas en gna1870 para proteccion de amplio espectro contra padecimientos causados por neisseria meningitidis.
WO2006088950A2 (en) 2005-02-14 2006-08-24 University Of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
DK2529619T3 (en) 2005-02-17 2016-01-11 Biogen Ma Inc Treatment of neurological disorders
AU2006216291B2 (en) 2005-02-27 2011-01-27 Institute For Antibodies Co., Ltd. Anti-IgSF4 antibody and utilization of the same
WO2006094134A2 (en) 2005-03-02 2006-09-08 Biogen Idec Ma Inc. Kim-1 antibodies for treatment of th2-mediated conditions
CA2600505C (en) 2005-03-10 2016-05-03 Morphotek, Inc. Anti-mesothelin antibodies
CA2601400A1 (en) 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
DK1866339T3 (da) 2005-03-25 2013-09-02 Gitr Inc GTR-bindende molekyler og anvendelser heraf
EP1875244B1 (de) 2005-03-30 2019-01-23 Minerva Biotechnologies Corporation Proliferation muc1 exprimierender zellen
ES2720288T3 (es) 2005-03-30 2019-07-19 Minerva Biotechnologies Corp Proliferación de células que expresan MUC1
CN101189023B (zh) 2005-03-31 2013-01-30 通用医疗公司 监测和调制hgf/hgfr活性
PL3264094T3 (pl) 2005-04-04 2021-04-19 Biogen Ma Inc. Sposoby oceniania odpowiedzi immunologicznej na środek leczniczy
JP2009521206A (ja) 2005-04-22 2009-06-04 モルフォテック、インク． 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体
EP1871809A2 (de) 2005-04-22 2008-01-02 Morphotek, Inc. Antikörper mit immuneffektor aktivität die in endosialin positive zellen internalisieren
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
US8034902B2 (en) 2005-05-04 2011-10-11 Quark Pharmaceuticals, Inc. Recombinant antibodies against CD55 and CD59 and uses thereof
CN101212967A (zh) 2005-05-10 2008-07-02 因塞特公司 吲哚胺2,3-双加氧酶调节剂及其用法
WO2006125076A2 (en) 2005-05-18 2006-11-23 Trinity Biosystems, Inc. Methods and compositions for immunizing against chlamydia infection
AU2006247039B2 (en) 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
CN101227924A (zh) 2005-05-26 2008-07-23 科罗拉多大学评议会 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制
SI2460831T1 (sl) 2005-05-27 2017-01-31 Biogen Ma Inc. Protitelesa, ki se vežejo na TWEAK
EP2364998A1 (de) 2005-06-16 2011-09-14 The Feinstein Institute for Medical Research Antikörper gegen HMGB1 und Fragmente davon
AU2006261127B2 (en) 2005-06-17 2012-03-15 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
ES2335232T3 (es) * 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
JP2009514790A (ja) 2005-07-22 2009-04-09 プロジェニクス・ファーマスーティカルズ・インコーポレイテッド Ｈｉｖ−１−感染患者におけるウイルス負荷を減少させる方法
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
US8652469B2 (en) 2005-07-28 2014-02-18 Novartis Ag M-CSF-specific monoclonal antibody and uses thereof
US8193328B2 (en) 2005-09-08 2012-06-05 Philadelphia Health & Education Corporation Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents
JP2009509970A (ja) 2005-09-22 2009-03-12 プロサイ インコーポレイテッド 酵母突然変異体において産生されるグリコシル化ポリペプチドおよびその使用方法
EP1946768A4 (de) 2005-10-28 2009-11-11 Meiji Seika Kaisha Aussenmantel-protein pa5158 von pseudomonas aeruginosa
EP1948680A4 (de) 2005-10-28 2010-01-13 Univ California Verfahren und verbindungen zum nachweis und zum isolieren von lymphomzellen
JP5198277B2 (ja) 2005-11-01 2013-05-15 アボツト・バイオテクノロジー・リミテツド バイオマーカーを用いて強直性脊椎炎を診断するための方法及び組成物
WO2007062037A2 (en) 2005-11-21 2007-05-31 Laboratoires Serono Sa Compositions and methods of producing hybrid antigen binding molecules and uses thereof
RU2432362C2 (ru) † 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
CN103638522A (zh) 2006-01-18 2014-03-19 通用医疗公司 增强淋巴功能的方法
WO2007096396A2 (en) 2006-02-22 2007-08-30 University Of Zurich Methods for treating autoimmune or demyelinating diseases
EP2377887A1 (de) 2006-03-10 2011-10-19 Zymogenetics Inc IL-17A- und IL-17F-bindende Antikörper und Verfahren zur ihrer Anwendung
WO2007108152A1 (ja) 2006-03-23 2007-09-27 Tohoku University 高機能性二重特異性抗体
SG170804A1 (en) 2006-03-30 2011-05-30 Meiji Seika Kaisha Pseudomonas aeruginosa outer membrane protein pa0427
EP2738179A1 (de) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antikörperreinigung
EP2666479A3 (de) 2006-04-10 2014-03-26 Abbott Biotechnology Ltd Anwendungen und Zusammensetzungen zur Behandlung von juveniler rheumatoider Arthritis
EP2666472A3 (de) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Anwendungen und Zusammensetzungen zur Behandlung von Psoriasis-Arthritis
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
BRPI0712607A8 (pt) 2006-05-25 2019-06-04 Biogen Idec Inc métodos de tratamento de acidente vascular cerebral
CN101495632B (zh) 2006-05-31 2011-08-03 安斯泰来制药有限公司 人源化抗人骨桥蛋白抗体
EP2035448A4 (de) 2006-06-01 2010-11-03 Elan Pharm Inc Neuroaktive fragmente von app
CA2655504A1 (en) 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
EP2041180B8 (de) 2006-06-19 2014-03-05 Liquidating Trust Ilt3-bindende moleküle und verwendungen davon
TWI542374B (zh) 2006-06-30 2016-07-21 艾伯維生物技術有限責任公司 自動注射裝置
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
EP2287189A1 (de) 2006-07-07 2011-02-23 Intercell AG Kleine Streptococcus pyogenes Antigene und die Verwendung davon
US7927590B2 (en) 2006-07-10 2011-04-19 Biogen Idec Ma Inc. Compositions and methods for inhibiting growth of smad4-deficient cancers
EP2078732B1 (de) 2006-07-10 2015-09-16 Fujita Health University Verfahren zur Identifikation möglicher diagnostischer oder therapeutischer Antikörper mittels Durchflusszytometrie
MX2009001341A (es) 2006-08-04 2009-05-28 Novartis Ag Anticuerpos especificos de ephb3 y usos de los mismos.
WO2008019403A1 (en) 2006-08-11 2008-02-14 University Of Medicine And Dentistry Of New Jersey Dual-sensitizer-containing luminescent compounds, conjugates, and uses thereof
HRP20140081T1 (hr) 2006-08-18 2014-03-28 Novartis Ag Prlr-specifiäśna antitijela i njihova uporaba
EP2500414A1 (de) 2006-09-13 2012-09-19 Abbott Laboratories Verbesserungen an Zellkulturen
MX345141B (es) 2006-09-13 2017-01-18 Abbvie Inc * Mejoras de cultivos celulares.
JPWO2008032833A1 (ja) 2006-09-14 2010-01-28 株式会社医学生物学研究所 Ａｄｃｃ活性を増強させた抗体及びその製造方法
FR2906533B1 (fr) 2006-09-28 2013-02-22 Pf Medicament Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
EP2094733A1 (de) 2006-11-03 2009-09-02 U3 Pharma GmbH Fgfr4-antikörper
CN101631802B (zh) 2006-11-10 2014-03-05 株式会社立富泰克 在体内具有抗肿瘤活性的抗人Dlk-1抗体
EP2084190B1 (de) 2006-11-17 2011-03-23 Novartis AG Lingo bindende moleküle und pharmazeutische verwendung davon
EP1923069A1 (de) 2006-11-20 2008-05-21 Intercell AG Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen
US8288110B2 (en) 2006-12-04 2012-10-16 Perkinelmer Health Sciences, Inc. Biomarkers for detecting cancer
MX2009006034A (es) 2006-12-07 2009-10-12 Novartis Ag Anticuerpos antagonistas contra ephb3.
EP2505651A3 (de) 2006-12-10 2013-01-09 Dyadic International, Inc. Pilzisolate mit reduzierter Proteaseaktivität
WO2008083169A2 (en) 2006-12-26 2008-07-10 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
US20080206235A1 (en) 2006-12-27 2008-08-28 Johns Hopkins University Compositions and methods for stimulating an immune response
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
EP2118309B1 (de) 2006-12-29 2015-01-28 The Regents of the University of Colorado, a body corporate Diagnostisches und therapeutisches ziel für autoimmunkrankheiten und verwendungen davon
SI2436696T1 (sl) 2007-01-05 2017-10-30 University Of Zurich Anti-beta-amiloidno protitelo in načini njegove uporabe
WO2008084072A2 (en) 2007-01-12 2008-07-17 Intercell Ag Protective proteins of s. agalactiae, combinations thereof and methods of using the same
WO2008098139A2 (en) 2007-02-07 2008-08-14 The Regents Of The University Of Colorado Axl tyrosine kinase inhibitors and methods of making and using the same
US20100136587A1 (en) 2007-02-16 2010-06-03 Margolin David H Method of Identifying Risk for Thyroid Disorder
PL2583978T3 (pl) 2007-02-23 2016-07-29 Prothena Biosciences Ltd Co Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
EP2124988B1 (de) 2007-02-23 2014-11-12 The Trustees of Columbia University in the City of New York Verfahren zur aktivierung oder blockierung des hla-e/qa-1-eingeschränkten cd8+ t-zellregulatorweges zur behandlung von immunerkrankungen
PL3067066T3 (pl) 2007-02-23 2019-09-30 Prothena Biosciences Limited Zapobieganie i leczenie choroby synukleinopatycznej i amyloidogennej
MX2009009926A (es) 2007-03-13 2010-03-15 Univ Zuerich Anticuerpo tumor-especifico humano monoclonal.
ME00832B (me) 2007-03-22 2012-03-20 Ucb Biopharma Sprl Vezivni proteini uključujući antitjela, derivate antitjela i fragmente antitjela, koji specifično vezuju cd154 i njihova upotreba
EP2137217B1 (de) 2007-04-05 2014-03-05 Morphotek, Inc. Verfahren zur hemmung der bindung von endosialin an liganden
EP2150564A2 (de) 2007-04-27 2010-02-10 ZymoGenetics, Inc. Il-17a-, il-17f- und il-23p19-antagonisten und verwendungsverfahren
WO2008135446A2 (en) 2007-05-02 2008-11-13 Intercell Ag Klebsiella antigens
US8962273B2 (en) 2007-05-11 2015-02-24 Genzyme Corporation Methods of producing a secreted protein
EP1997830A1 (de) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
US7709215B2 (en) 2007-06-01 2010-05-04 Cytonics Corporation Method for diagnosing and treating acute joint injury
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
JP2010529999A (ja) 2007-06-14 2010-09-02 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗体製剤
US20100203075A1 (en) 2007-06-18 2010-08-12 Intercell Ag Chlamydia antigens
US8921279B2 (en) 2007-06-26 2014-12-30 F-Star Biotechnologische Forschungs—und Entwicklungsges. m.b.H Display of binding agents
JP5238942B2 (ja) 2007-06-27 2013-07-17 国立大学法人大阪大学 ペリオスチンのＥｘｏｎ−１７部位によりコードされるペプチドに対する抗体を含む癌治療剤
EP2014681A1 (de) 2007-07-12 2009-01-14 Pierre Fabre Medicament Neue Antikörper zur Hemmung der C-Met-Dimerisation und Verwendungen davon
AU2008275589B2 (en) 2007-07-12 2013-11-21 Gitr, Inc. Combination therapies employing GITR binding molecules
US8153595B2 (en) 2007-07-13 2012-04-10 The Johns Hopkins University B7-DC variants immunogenic compositions and methods of use thereof
SI2185198T1 (sl) 2007-08-02 2015-04-30 Gilead Biologics, Inc. Inhibitorji LOX in LOXL2 ter njihova uporaba
WO2009028639A1 (ja) 2007-08-30 2009-03-05 Daiichi Sankyo Company, Limited 抗ｅｐｈａ２抗体
CN101848999A (zh) * 2007-09-06 2010-09-29 国立大学法人大阪大学 抗-cd20单克隆抗体
WO2009033071A2 (en) 2007-09-07 2009-03-12 Dyadic International, Inc. Novel fungal enzymes
EP2185592B1 (de) 2007-09-13 2013-01-23 University Of Zurich Prorektorat Forschung Monoklonaler amyloid-beta (abeta)-spezifischer antikörper und seine verwendung
EP4512422A3 (de) 2007-09-14 2025-05-21 Amgen Inc. Homogene antikörperpopulationen
CN108130327A (zh) 2007-10-11 2018-06-08 第三共株式会社 靶向破骨细胞相关蛋白Siglec-15的抗体
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
JPWO2009051220A1 (ja) 2007-10-19 2011-03-03 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
CA2866649A1 (en) 2007-11-01 2009-05-07 University Of Iowa Research Foundation Rca locus analysis to assess susceptibility to amd and mpgnii
BRPI0818928B1 (pt) 2007-11-02 2021-12-07 Novartis Ag Moléculas de ligação a nogo-a isoladas, seu método de produção e seu uso, polinucleotídeo isolado, vetor e sistema de expressão, célula hospedeira isolada, e composição farmacêutica
US8415361B2 (en) 2007-11-09 2013-04-09 The Salk Institute For Biological Studies Use of TAM receptor inhibitors as antimicrobials
SG186000A1 (en) 2007-11-12 2012-12-28 U3 Pharma Gmbh Axl antibodies
KR101614364B1 (ko) 2007-11-28 2016-04-22 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 유인원 ｅ 아데노바이러스 ｓａｄｖ-39, -25.2, -26, -30, -37, 및 -38
EP2220217A2 (de) 2007-11-28 2010-08-25 The Trustees of the University of Pennsylvania Simian-adenoviren sadv-40, -31 und-34 der unterfamilie c und anwendungen davon
WO2009079242A2 (en) 2007-12-05 2009-06-25 Massachusetts Institute Of Technology Aglycosylated immunoglobulin mutants
WO2009078799A1 (en) 2007-12-17 2009-06-25 Marfl Ab New vaccine for the treatment of mycobacterium related disorders
KR20100100941A (ko) 2007-12-25 2010-09-15 메이지 세이카 가부시키가이샤 녹농균의 ⅲ형 분비 장치 구성 단백질 ｐａ1698
DK2237803T3 (en) 2007-12-28 2015-10-05 Prothena Biosciences Ltd Treatment and prophylaxis of amyloidosis
DK2242769T3 (en) 2008-01-11 2017-02-06 Adheron Therapeutics Inc ANTI-CADHERIN-11 EC1 DOMAIN ANTIBODIES FOR TREATMENT OF INFLAMMATORY LED DISEASES
CA2711882C (en) 2008-01-11 2016-07-19 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Improved humanized anti-human .alpha.9-integrin antibody
EP2245156A4 (de) * 2008-01-11 2011-02-02 Gene Techno Science Co Ltd Humanisierte anti- 9-integrin-antikörper und verwendungen davon
CA2714413C (en) 2008-02-08 2017-01-24 Immunas Pharma, Inc. Antibody capable of binding specifically to ab-oligomer, and use thereof
CA2716928C (en) 2008-03-04 2018-04-10 The Trustees Of The University Of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
CA2717812A1 (en) 2008-03-13 2009-09-17 Biotest Ag Agent for treating disease
CA2718184A1 (en) 2008-03-13 2009-10-08 Biotest Ag Agent for treating disease
JP5795167B2 (ja) 2008-03-13 2015-10-14 バイオテスト・アクチエンゲゼルシヤフト 疾患治療剤
US8840901B2 (en) 2008-03-17 2014-09-23 Universitaetsklinikum Muenster YopM as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions
EP2275537B1 (de) 2008-03-17 2014-12-24 Livtech Inc. Anti-mensch-dlk-1-antikörper mit antikörperaktivität in vivo
US8241643B2 (en) 2008-03-17 2012-08-14 Intercell Ag Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
JPWO2009119794A1 (ja) 2008-03-27 2011-07-28 タカラバイオ株式会社 感染症予防、治療剤
JP5752592B2 (ja) 2008-04-11 2015-07-22 シアトル ジェネティックス， インコーポレイテッド 膵臓癌、卵巣癌、および他の癌の検出および処置
EP2113255A1 (de) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Zytotoxisches Immunglobulin
EP2282773B2 (de) 2008-05-02 2025-03-05 Seagen Inc. Verfahren und zusammensetzungen zur herstellung von antikörpern und antikörperderivaten mit reduzierter kernfukosylierung
EP2300034B1 (de) 2008-06-02 2018-08-08 Dana-Farber Cancer Institute, Inc. Pharmazeutische zusammensetzung zur zur behandlung oder vorbeugung von multiplem myelom oder waldenström-makroglobulinämie
EP2319869B1 (de) 2008-06-20 2016-08-17 National University Corporation Okayama University ANTIKÖRPER GEGEN DEN OXIDIERTES LDL/ß²GPI-KOMPLEX UND ANWENDUNG DAVON
AU2009264564B2 (en) 2008-06-25 2014-05-08 Novartis Ag Stable and soluble antibodies inhibiting TNFalpha
MX2011000052A (es) 2008-06-25 2011-07-29 Esbatech Alcon Biomed Res Unit Humanizacion de anticuerpos de conejos usando una estructura de anticuerpos universal.
SI2752428T1 (sl) 2008-06-25 2020-03-31 Novartis Ag Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa
CN104042611B (zh) 2008-07-08 2019-05-14 因塞特控股公司 作为吲哚胺2，3-双加氧酶的抑制剂的1，2，5-噁二唑
EP2322610B1 (de) 2008-07-16 2016-12-14 Medical and Biological Laboratories Co., Ltd. Anti-human-clcp1-antikörper und seine anwendung
US8961991B2 (en) 2009-03-10 2015-02-24 Baylor Research Institute Anti-CD40 targeted fusion proteins
EP2322220B1 (de) 2008-08-01 2014-01-01 Axis, Inc. Therapeutikum bzw. prophylaktikum für osteoarthritis
US8795981B2 (en) 2008-08-08 2014-08-05 Molecular Devices, Llc Cell detection
US8417011B2 (en) 2008-09-18 2013-04-09 Molecular Devices (New Milton) Ltd. Colony detection
EP2172485A1 (de) 2008-10-01 2010-04-07 Pierre Fabre Medicament Neuartige Anti-CXCR4-Antikörper und ihre Verwendung bei der Krebsbehandlung
US8715654B2 (en) 2008-10-02 2014-05-06 Celtaxsys, Inc. Methods of modulating the negative chemotaxis of immune cells
US11898160B2 (en) 2008-10-09 2024-02-13 Minerva Biotechnologies Corporation Method for maintaining pluripotency in cells
EP2346904B1 (de) 2008-10-29 2017-04-12 China Synthetic Rubber Corporation Methoden und mittel zur diagnose und behandlung von hepatozellulärem karzinom
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8940290B2 (en) 2008-10-31 2015-01-27 The Trustees Of The University Of Pennsylvania Simian adenoviruses SAdV-43, -45, -46, -47, -48, -49, and -50 and uses thereof
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
AR074439A1 (es) 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
US9469691B2 (en) 2008-12-02 2016-10-18 Pierre Fabre Medicament Anti-cMET antibody
EA030826B1 (ru) 2008-12-19 2018-10-31 Панима Фармасьютикалз Аг ЧЕЛОВЕЧЕСКИЕ АУТОАНТИТЕЛА ПРОТИВ α-СИНУКЛЕИНА
US8313915B2 (en) 2009-01-21 2012-11-20 Gundersen Lutheran Medical Foundation, Inc. Early detection of canine lyme disease by specific peptides and antibodies
WO2010085590A1 (en) 2009-01-23 2010-07-29 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid gram positive bacteria
WO2010089340A2 (en) 2009-02-05 2010-08-12 Intercell Ag Peptides protective against e. faecalis, methods and uses relating thereto
US8617574B2 (en) 2009-02-13 2013-12-31 Valneva Austria Gmbh Nontypable Haemophilus influenzae antigens
US20110306069A1 (en) 2009-02-19 2011-12-15 Qingyu Wu Corin As A Marker For Heart Failure
CN103415534A (zh) 2009-03-10 2013-11-27 贝勒研究院 靶向抗原呈递细胞的癌症疫苗
AU2010222942B2 (en) 2009-03-10 2013-01-10 Baylor Research Institute Anti-CD40 antibodies and uses thereof
EP2412808B1 (de) 2009-03-25 2016-09-07 Tohoku University Bispezifischer lh-antikörper
US8575316B2 (en) 2009-04-09 2013-11-05 Daiichi Sankyo Company, Limited Anti-Siglec-15 antibody
JP2012523438A (ja) 2009-04-10 2012-10-04 タフツ メディカル センター インコーポレイテッド メタロプロテイナーゼ−１（ｍｍｐ−１）によるｐａｒ−１活性化
JP5812418B2 (ja) 2009-04-17 2015-11-11 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
EP2246364A1 (de) 2009-04-29 2010-11-03 Pierre Fabre Médicament Antikörper gegen CXCR4 zur Behandlung von HIV
RU2524487C2 (ru) 2009-04-29 2014-07-27 Эббви Байотекнолоджи Лтд Автоматическое инъекционное устройство
EP2270053A1 (de) 2009-05-11 2011-01-05 U3 Pharma GmbH Humanisierte AXL-Antikörper
US8846031B2 (en) 2009-05-29 2014-09-30 The Trustees Of The University Of Pennsylvania Simian adenovirus 41 and uses thereof
EP2260864A1 (de) 2009-06-10 2010-12-15 University of Melbourne Therapeutische Anwendungen
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
US10087252B2 (en) 2009-07-24 2018-10-02 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with αvβ5 integrin
JP5426026B2 (ja) 2009-07-28 2014-02-26 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 非侵襲性インビボ光学イメージング方法
AU2010280981B2 (en) 2009-08-05 2016-01-28 Nexigen Gmbh Human HCV-interacting proteins and methods of use
WO2011024114A1 (en) 2009-08-25 2011-03-03 Ecole Polytechnique Federale De Lausanne (Epfl) Targeting extracellular matrix molecules for the treatment of cancer
TWI412375B (zh) 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
WO2011026122A2 (en) 2009-08-31 2011-03-03 Amplimmune, Inc. B7-h4 fusion proteins and methods of use thereof
CA2774326C (en) 2009-09-14 2023-11-07 Donald Bellgrau Modulation of yeast-based immunotherapy products and responses
EP2305285A1 (de) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Mittel und Verfahren zur Behandlung von ischämischen Erkrankungen
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
EP2308897A1 (de) 2009-10-09 2011-04-13 Pierre Fabre Medicament Chimäre Antikörper spezifisch für CD151 und deren Verwendung zur Behandlung von Krebs
WO2011044553A1 (en) 2009-10-11 2011-04-14 Biogen Idec Ma Inc. Anti-vla-4 related assays
US8921525B2 (en) 2009-11-18 2014-12-30 Tohoku University Highly-functional mutant of humanized anti-EGFR antibody variable region
EP2332929A1 (de) 2009-11-25 2011-06-15 ArisGen SA Orthoester-Derivate aus Kronenäthern als Träger für diagnostische und pharmazeutische Zusammensetzungen
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
WO2011068870A2 (en) 2009-12-01 2011-06-09 President And Fellows Of Harvard College Modulation of nk cell antigen specific effector activity by modulation of cxcr6 (cd186)
WO2011075578A1 (en) 2009-12-16 2011-06-23 Philip Bosch Methods of treating interstitial cystitis
US9221759B2 (en) 2010-01-13 2015-12-29 Rutgers, The State University Of New Jersey Fluorophore chelated lanthanide luminescent probes with improved quantum efficiency
WO2011091181A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
CA2787783A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Anti-ilt5 antibodies and ilt5-binding antibody fragments
JP2012246222A (ja) 2010-01-29 2012-12-13 Axis Inc 変形性関節症治療剤または予防剤を製造するための使用
WO2011093081A1 (ja) 2010-01-29 2011-08-04 Ａｘｉｓ株式会社 変形性関節症治療剤を含有する注射剤
AU2011210465A1 (en) 2010-01-29 2012-08-23 Axis Inc. Pharmaceutical composition for treatment or prevention of osteoarthritis, and method of production therefor
US20120014956A1 (en) 2010-02-02 2012-01-19 Hartmut Kupper Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor
PH12012501545B1 (en) 2010-02-08 2018-08-03 Agensys Inc Antibody drug conjugates (adc) that bind to 161p2f10b proteins
EP4219560A3 (de) 2010-02-18 2023-08-23 The Regents of The University of California Integrin alpha v beta 8 neutralisierender antikörper
EP2544688B1 (de) 2010-03-02 2016-09-07 President and Fellows of Harvard College Verfahren und zusammensetzungen zur behandlung des angelman-syndroms
EP2542571B1 (de) * 2010-03-03 2016-05-25 The University of British Columbia Oligomer-spezifisches amyloid-beta-epitop und antikörper dazu
AU2011231558B2 (en) 2010-03-26 2016-08-11 Westfaelische Wilhelms-Universitaet Muenster Substitute therapy for glucocorticoids
EP2371863A1 (de) 2010-03-30 2011-10-05 Pierre Fabre Médicament Menschlische Antikörper gegen CXCR4 zur Behandlung von Krebs
ES2699591T3 (es) 2010-04-09 2019-02-11 Critical Care Diagnostics Inc Anticuerpos contra ST-2 humana soluble y ensayos
MX340683B (es) 2010-04-16 2016-07-21 Biogen Ma Inc Anticuerpos anti-vla-4.
CA2796186C (en) 2010-04-21 2019-04-09 Abbott Biotechnology Ltd. Wearable automatic injection device for controlled delivery of therapeutic agents
EP2567234B1 (de) 2010-05-07 2018-09-19 F.Hoffmann-La Roche Ag Diagnoseverfahren zum Nachweis von Zellen ex vivo
BR112012029281B1 (pt) 2010-05-17 2020-12-08 Livtech, Inc anticorpo contra trop-2 humano, anticorpo monoclonal contra trop-2 humano, fragmento de anticorpo derivado de anticorpo, hibridoma, conjugado, composição farmacêutica, uso de composição farmacêutica, método para detectar um tumor e kit para tratar, diagnosticar ou detectar um tumor
WO2011146727A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of treating interstitial cystitis
JP5619162B2 (ja) 2010-07-08 2014-11-05 本田技研工業株式会社 高周波加熱用コイル
EP2593475B1 (de) 2010-07-14 2016-03-02 Merck Sharp & Dohme Corp. Monoklonaler antikörper gegen addl und anwendungen davon
CN107090039A (zh) 2010-07-15 2017-08-25 亚德赫伦医疗公司 靶向于钙粘着蛋白‑11的ec1结构域的人源化抗体及相关组合物和方法
CA2806438C (en) 2010-07-29 2021-04-13 Eleven Biotherapeutics, Inc. Chimeric il-1 receptor type i agonists and antagonists
JP2012034668A (ja) 2010-08-12 2012-02-23 Tohoku Univ ヒト型化抗ｅｇｆｒ抗体リジン置換可変領域断片及びその利用
WO2012027494A1 (en) 2010-08-24 2012-03-01 Regents Of The University Of Minnesota Bispecific targeting reagents
JP2013540991A (ja) 2010-08-27 2013-11-07 ユニバーシティ・オブ・チューリッヒ 炎症および／または心血管疾患における新規診断および治療標的
EP2609431B1 (de) 2010-08-27 2017-05-10 University of Zurich Verfahren für target- und wirkstoffvalidierung bei entzündungs- und/oder herz-kreislauf-erkrankungen
WO2012028697A1 (en) 2010-09-01 2012-03-08 Eth Zürich, Institute Of Molecular Biology And Biophysics Affinity purification system based on donor strand complementation
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
US8497138B2 (en) 2010-09-30 2013-07-30 Genetix Limited Method for cell selection
EP2623119B1 (de) 2010-09-30 2017-06-14 Riken MEDIKAMENT ZUR VERWENDUNG IN GLIOMBEHANDLUNGSVERFAHREN, GLIOMUNTERSUCHUNGSVERFAHREN, VERFAHREN ZUR ABGABE EINEr GRWÜNSCHTEN VERBINDUNG AN EIN GLIOM
PT2627672T (pt) 2010-10-11 2018-11-16 Univ Zuerich Anticorpos anti-tau humanos
CA2814652C (en) 2010-10-13 2021-05-18 Janssen Biotech, Inc. Human oncostatin m antibodies and methods of use
JP5995851B2 (ja) 2010-10-18 2016-09-21 メディアファーマ エス． アール． エル．Ｍｅｄｉａｐｈａｒｍａ Ｓ． Ｒ． Ｌ． ＥｒｂＢ３結合抗体
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
TWI545134B (zh) 2010-10-22 2016-08-11 西雅圖遺傳學公司 以奧裡斯他汀（ＡＵＲＩＳＴＡＴＩＮ）為主之抗體藥物結合物及ＰＩ３Ｋ－ＡＫＴ ｍＴＯＲ路徑抑制劑間的協同功效
EP3722808B1 (de) 2010-10-25 2024-09-11 Biogen MA Inc. Verfahren zur bestimmung von unterschieden in einer alpha-4-integrin-aktivität durch korrelation von unterschieden in svcam- und/oder smadcam-ebenen
JP2014504147A (ja) 2010-10-27 2014-02-20 ピエール、ファーブル、メディカマン Ｈｉｖの治療用抗体
RS54846B1 (sr) 2010-10-29 2016-10-31 Daiichi Sankyo Co Ltd Novo anti-dr5 antitelo
EP2640425A2 (de) 2010-11-18 2013-09-25 Beth Israel Deaconess Medical Center, Inc. Verfahren zur behandlung von adipositas durch hemmung von nicotinamid-n-methyl-transferase (nnmt)
CN103874707B (zh) 2010-11-19 2017-04-19 卫材R&D管理有限公司 中和抗‑ccl20抗体
AU2011332025B2 (en) 2010-11-23 2015-06-25 The Trustees Of The University Of Pennsylvania Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof
JP6067575B2 (ja) 2010-12-17 2017-01-25 ニューリミューン ホールディング エイジー ヒト抗ｓｏｄ１抗体
EP2659910B1 (de) 2010-12-27 2016-11-09 National University Corporation Nagoya University Screeningverfahren zur Identifizierung von Verbindungen die die durch Rezeptortyrosinkinase vermittelte Prosurvival-Signalisierung in Krebszellen hemmen
US20130295091A1 (en) 2011-01-10 2013-11-07 University Of Zurich Combination therapy including tumor associated antigen binding antibodies
PT2663579T (pt) 2011-01-14 2017-07-28 Univ California Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização
AU2012209223B2 (en) 2011-01-24 2015-11-05 Abbvie Biotechnology Ltd Automatic injection devices having overmolded gripping surfaces
WO2012104824A1 (en) 2011-02-04 2012-08-09 Ecole polytechnique fédérale de Lausanne (EPFL) Therapeutic antibodies targeting app-c99
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
WO2012110843A1 (en) 2011-02-18 2012-08-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for promoting fibrinolysis and thrombolysis
WO2012113775A1 (en) 2011-02-21 2012-08-30 University Of Zurich Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
EP2683290B1 (de) 2011-03-07 2018-11-07 F.Hoffmann-La Roche Ag Verfahren zum in-vivo-testen von therapeutischen antikörpern
EP2683413A1 (de) 2011-03-07 2014-01-15 F.Hoffmann-La Roche Ag In-vivo-auswahl therapeutisch aktiver antikörper
US10139420B2 (en) 2011-03-09 2018-11-27 ISNERM (Institut National de la Sante et de la Recherche Medicale) Methods for treating vaso-occlusive crisis using non-modified annexin V
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
EP2686418A4 (de) 2011-03-17 2015-04-22 Minerva Biotechnologies Corp Verfahren zur herstellung pluripotenter stammzellen
JP5955871B2 (ja) 2011-03-17 2016-07-20 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔｃｒアルファ／ベータを枯渇させた細胞調製物
EP2688592A4 (de) 2011-03-25 2015-07-22 Baylor Res Inst Zusammensetzungen und verfahren zur immunisierung gegen den hepatitis-c-virus
TW201249867A (en) 2011-04-01 2012-12-16 Astellas Pharma Inc Novel anti-human il-23 receptor antibody
US9956345B2 (en) 2011-04-21 2018-05-01 Abbvie Inc. Wearable automatic injection device for controlled administration of therapeutic agents
ES2667568T3 (es) 2011-04-25 2018-05-11 Daiichi Sankyo Company, Limited Anticuerpo anti-B7-H3
WO2012151247A2 (en) 2011-05-02 2012-11-08 Millennium Pharmaceuticals, Inc. FORMULATION FOR ANTI-α4β7 ANTIBODY
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
WO2012154889A1 (en) 2011-05-09 2012-11-15 The Cleveland Clinic Foundation Serum s100b and uses thereof
WO2012163848A1 (en) 2011-05-27 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of crohn's disease
EP2530088A1 (de) 2011-05-30 2012-12-05 Klinikum rechts der Isar der Technischen Universität München Mittel und Verfahren zur Diagnose und Behandlung von Multipler Sklerose
US20140186363A1 (en) 2011-06-03 2014-07-03 University Of Zurich Magea3 binding antibodies
US20140093514A1 (en) 2011-06-03 2014-04-03 University Of Zurich Magea3 binding antibodies
EP2718327A1 (de) 2011-06-06 2014-04-16 Neotope Biosciences Limited Mcam-antagonisten und behandlungsverfahren
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
US20140120555A1 (en) 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
ES2699801T3 (es) 2011-06-23 2019-02-12 Biogen Int Neuroscience Gmbh Moléculas de unión anti-alfa sinucleína
DE202011103324U1 (de) 2011-07-12 2012-01-02 Nekonal S.A.R.L. Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
WO2013014262A1 (en) 2011-07-27 2013-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating myhre syndrome
NO2743348T3 (de) 2011-08-11 2018-06-09
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
JP5925783B2 (ja) 2011-08-12 2016-05-25 国立感染症研究所長 アスペルギルスフミガーツス感染症の検査、予防及び治療のための方法並びに組成物
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
KR20210099167A (ko) 2011-09-19 2021-08-11 악손 뉴로사이언스 에스이 알쯔하이머병의 타우 매개된 병리학의 단백질 기재 요법 및 진단
GB2495115A (en) * 2011-09-29 2013-04-03 Oxford Plastic Sys Ltd Base for supporting temporary fence panels or posts.
TW201329105A (zh) 2011-10-04 2013-07-16 Thr Trustees Of Columbia University In The City Of New York 人類ｎｏｔｃｈ１引誘物
EP2764118A1 (de) 2011-10-05 2014-08-13 University of Bremen Wnt4 und med12 zur verwendung bei der diagnose und behandlung von tumorerkrankungen
WO2013050441A1 (en) 2011-10-05 2013-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
US10378060B2 (en) 2011-10-14 2019-08-13 Dana-Farber Cancer Institute, Inc. ZNF365/ZFP365 biomarker predictive of anti-cancer response
AU2012326137B2 (en) 2011-10-17 2018-11-29 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
EP2768971A1 (de) 2011-10-20 2014-08-27 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren zur erkennung und behandlung von kardialer remodellierung
EP2589609A1 (de) 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigenbindendes Protein und dessen Verwendung als Adressierungsprodukt bei der Behandlung von Krebs
US20140328864A1 (en) 2011-11-22 2014-11-06 Inserm (Institut National De La Sente Et De La Recherche Medicale) Methods and pharmaceutical compositions for reducing airway hyperresponse
US9427464B2 (en) 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
ES2638649T3 (es) 2011-11-28 2017-10-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Composición farmacéutica para su uso en el tratamiento de disfunciones asociadas al envejecimiento
EP2602621A1 (de) 2011-12-08 2013-06-12 Julius-Maximilians-Universität Würzburg LASP-1, neuer Harnmarker zur Erkennung eines Übergangszellenkarzinoms
CN109276713A (zh) * 2011-12-13 2019-01-29 诺帝克纳诺维科特股份公司 嵌合的治疗性抗-cd37抗体hh1
FR2984750B1 (fr) 2011-12-23 2014-01-10 Lfb Biotechnologies Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
WO2013093122A2 (en) 2011-12-23 2013-06-27 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
SI2797952T1 (sl) 2011-12-28 2019-07-31 Immunoqure Ag Postopek za pripravo monoklonskih avto-protiteles z želeno specifičnostjo
CA2858336A1 (en) 2012-01-01 2013-07-04 Qbi Enterprises Ltd. Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
AU2013216863B2 (en) 2012-02-10 2018-09-06 Seagen Inc. Detection and treatment of CD30+ cancers
ES2732243T3 (es) 2012-02-16 2019-11-21 Santarus Inc Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
KR102051505B1 (ko) 2012-02-23 2019-12-03 다이이치 산쿄 유럽 게엠베하 방사선 감수성 조절을 위한 ｈｅｒ３ 억제제
JP6137169B2 (ja) 2012-02-28 2017-05-31 アステラス製薬株式会社 新規抗ヒトｉｌ−２３受容体抗体
CN104284678B (zh) 2012-03-15 2018-04-24 詹森生物科技公司 人抗cd27抗体、方法和用途
PL2828284T3 (pl) 2012-03-20 2019-11-29 Biogen Ma Inc Przeciwciała neutralizujące wirus jc
HK1204657A1 (en) 2012-03-30 2015-11-27 Daiichi Sankyo Company, Limited Anti-siglec15 antibody with modified cdr
CN104321430A (zh) 2012-03-30 2015-01-28 第一三共株式会社 新颖的抗-siglec-15抗体
ES2702278T3 (es) 2012-04-01 2019-02-28 Technion Res & Dev Foundation Péptidos de inductor de metaloproteinasa de matriz extracelular (emmprin) y anticuerpos de unión
CN103382223B (zh) 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
US8999657B2 (en) 2012-04-02 2015-04-07 Gundersen Lutheran Health System Reagents, methods, and kits for the classification of cancer
JP6188681B2 (ja) 2012-04-09 2017-08-30 第一三共株式会社 抗ｆｇｆｒ２抗体
TWI606065B (zh) 2012-04-27 2017-11-21 第一三共股份有限公司 抗ｒｏｂｏ４抗體
US9062120B2 (en) 2012-05-02 2015-06-23 Janssen Biotech, Inc. Binding proteins having tethered light chains
US9416189B2 (en) 2012-05-11 2016-08-16 Microbial Chemistry Research Foundation Anti-CXADR antibody
JP6122948B2 (ja) 2012-05-15 2017-04-26 モルフォテック， インコーポレイテッド 胃癌の治療のための方法
BR112014028684A2 (pt) 2012-05-18 2017-07-25 Univ Pennsylvania subfamília e adenovírus de símio a1302, a1320, a1331 e a1337 e usos dos mesmos
WO2013174834A1 (en) 2012-05-22 2013-11-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating focal segmental glomerulosclerosis
JP5868549B2 (ja) 2012-05-24 2016-02-24 マウントゲイト グループ リミテッド 狂犬病感染の予防および治療に関する組成物および方法
MX2015000438A (es) 2012-07-13 2016-04-25 Univ Pennsylvania Manejo de toxicidad para actividad antitumoral de cars.
PL2875049T3 (pl) 2012-07-18 2019-07-31 Institut National De La Santé Et De La Recherche Médicale (Inserm) Sposoby zapobiegania i leczenia przewlekłej choroby nerek (ckd)
RU2015105588A (ru) 2012-07-19 2016-09-10 Редвуд Байосайнс, Инк. Антитело, специфическое к cd22, и способы его применения
WO2014021339A1 (ja) 2012-07-30 2014-02-06 国立大学法人名古屋大学 ヒトミッドカインに対するモノクローナル抗体
DK3489261T3 (da) 2012-08-24 2020-12-14 Univ California Antistoffer og vacciner til anvendelse ved behandling af ror1-cancere og hæmning af metastase
TWI660972B (zh) 2012-09-10 2019-06-01 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
AU2013316441B2 (en) 2012-09-13 2018-08-09 Chugai Seiyaku Kabushiki Kaisha Gene knock-in non-human animal
EP2711016A1 (de) 2012-09-21 2014-03-26 Covagen AG Neue IL-17A-Verbindungsmoleküle und medizinische Verwendungen davon
SI2905335T1 (en) 2012-10-03 2018-04-30 Chiome Bioscience Inc. Anti-human dlk-1 antibody having anti-tumor activity in vivo
ES2776029T3 (es) 2012-10-08 2020-07-28 St Jude Childrens Res Hospital Terapias basadas en el control de la estabilidad y función de las células T reguladoras por medio de un eje neuropilina-1:semaforina
WO2014057687A1 (ja) 2012-10-11 2014-04-17 第一三共株式会社 抗体－薬物コンジュゲート
DE102012020496A1 (de) 2012-10-18 2014-04-24 Charité - Universitätsmedizin Berlin Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
WO2014064203A1 (en) 2012-10-26 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
JP6694712B2 (ja) 2012-11-01 2020-05-20 マックス−デルブルック−セントラム フアー モレキュラーレ メデジン Ｃｄ２６９（ｂｃｍａ）に対する抗体
AR093357A1 (es) 2012-11-05 2015-06-03 Pf Medicament Proteinas de union al antigeno y su utilizacion como producto de direccionamiento para el tratamiento del cancer
WO2014072416A1 (en) 2012-11-08 2014-05-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of bone metastases
TW201438736A (zh) 2012-11-14 2014-10-16 Regeneron Pharma 以ｄｌｌ４拮抗劑治療卵巢癌之方法
WO2014093396A1 (en) 2012-12-10 2014-06-19 Biogen Idec Ma Inc. Anti-blood dendritic cell antigen 2 antibodies and uses thereof
CA2894225A1 (fr) 2012-12-17 2014-06-26 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
US10024844B2 (en) 2012-12-20 2018-07-17 Hospital For Special Surgery Identification of an inhibitor of iRhom1 or an inhibitor of iRhom2
AU2013361107B2 (en) 2012-12-21 2018-08-23 Biogen International Neuroscience Gmbh Human anti-tau antibodies
US9771413B2 (en) 2012-12-31 2017-09-26 Neurimmune Holding Ag Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
EP2752426A1 (de) 2013-01-03 2014-07-09 Covagen AG Humane Serumalbumin bindende Verbindungen und Fusionsproteine daraus
ES2865735T3 (es) 2013-01-28 2021-10-15 Evec Inc Anticuerpo anti-hmgb1 humanizado o fragmento de unión a antígeno del mismo
WO2014118317A1 (en) 2013-02-01 2014-08-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting and preventing metastasis in triple negative breast cancers
US9932396B2 (en) 2013-02-08 2018-04-03 Medical & Biological Laboratories Co., Ltd. Antibody against human NRG1 protein
EP2956478A1 (de) 2013-02-15 2015-12-23 ESBATech - a Novartis Company LLC Akzeptorrahmen für pcdr-fropfung
RU2015139890A (ru) 2013-02-20 2017-03-27 ИЭсБиЭйТЕК - Э НОВАРТИС КОМПАНИ ЭлЭлСи Акцепторный каркасный участок для пересадки cdr
FR3004184B1 (fr) 2013-02-26 2016-03-18 Agronomique Inst Nat Rech Anticorps anti-gluten desamide et utilisations.
ES2673583T3 (es) 2013-02-28 2018-06-22 National Cancer Center Anticuerpo contra fibrina insoluble
EP2966087B1 (de) 2013-03-08 2020-05-06 Osaka University Antikörper gegen durch exon-21 von periostin kodiertes peptid und pharmazeutische zusammensetzung zur prävention oder behandlung von entzündungsbedingten erkrankungen damit
KR102236926B1 (ko) 2013-03-13 2021-04-06 세센 바이오, 아이엔씨. 안구 운반을 위한 키메릭 사이토카인 제제
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP2968550B1 (de) 2013-03-14 2018-11-14 Ffe Therapeutics LLC Zusammensetzungen und verfahren zur behandlung von angiogenesebedingten erkrankungen
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
CA2903546A1 (en) 2013-03-15 2014-09-25 Biogen Ma Inc. Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
JP2016515544A (ja) 2013-03-18 2016-05-30 バイオセルオーエックス プロダクツ ビー．ブイ． ヒト化抗ｃｄ１３４（ｏｘ４０）抗体およびその使用
EP3747907A3 (de) 2013-04-01 2021-02-24 The Regents of the University of California Verfahren und zusammensetzungen zur behandlung und prävention von mit avb8-integrin assoziierten krankheiten
WO2014174596A1 (ja) 2013-04-23 2014-10-30 株式会社医学生物学研究所 ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体
US9717648B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN107460201A (zh) 2013-05-08 2017-12-12 科济生物医药（上海）有限公司 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
EP3159695A3 (de) 2013-06-20 2017-07-05 The Trustees of The University of Pennsylvania Verfahren zur diagnose von bauchspeicheldrüsenkrebs
AU2014286131C1 (en) 2013-07-03 2020-02-13 Immunoqure Ag Human anti-IFN-alpha antibodies
EP3016973A1 (de) 2013-07-05 2016-05-11 INSERM - Institut National de la Santé et de la Recherche Médicale Neuartige alternative splice-transkripte für ketten-alpha der mhc-klasse i (mica) und verwendungen davon
CN105517572B (zh) 2013-07-05 2019-05-31 华盛顿大学商业中心 用于治疗癌症的中和可溶性mic的单克隆抗体
MY177098A (en) 2013-08-09 2020-09-05 Astellas Pharma Inc Novel anti-human tslp receptor antibody
WO2015036956A1 (en) 2013-09-12 2015-03-19 Institut National De La Sante Et De La Recherche Medicale Method for in vitro quantifying allo-antibodies, auto-antibodies and/or therapeutic antibodies
CA2924020A1 (en) 2013-09-20 2015-03-26 Westfaelische Wilhelms-Universitaet Muenster Cell-penetrating bacterial e3-ubiqitin-ligases for use in immunotherapy
CA2925087C (en) 2013-09-24 2024-02-13 The Feinstein Institute For Medical Research Peptides inhibiting cold-inducible rna binding protein activity
ES2894333T3 (es) 2013-09-26 2022-02-14 Beth Israel Deaconess Medical Ct Inc Inhibidores de SGK1 en el tratamiento del síndrome de QT Largo
EP3835422A1 (de) 2013-09-30 2021-06-16 Daiichi Sankyo Company, Limited Anti-lps-o11-antikörper
ES2714708T3 (es) 2013-10-01 2019-05-29 Mayo Found Medical Education & Res Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim
JP6509735B2 (ja) 2013-10-08 2019-05-08 第一三共株式会社 抗ｆｇｆｒ２抗体と他剤の組合せ
EP3070167A4 (de) 2013-11-06 2017-06-07 Osaka University Antikörper mit breiter neutralisierender aktivität bei einem gruppe-1-influenza-a-virus
EA034655B1 (ru) 2013-11-06 2020-03-03 Янссен Байотек, Инк. Антитела к ccl17
JP2016538286A (ja) 2013-11-15 2016-12-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 膵臓癌を処置するための方法及び医薬組成物
WO2015082446A1 (en) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-cdcp1 antibody and a taxane
US10294301B2 (en) 2013-12-24 2019-05-21 Astellas Pharma Inc. Anti-human BDCA-2 antibody
SI3424955T1 (sl) 2013-12-25 2025-08-29 Daiichi Sankyo Company, Limited Metoda za proizvodnjo konjugata protitelo-zdravilo anti-trop2
EP3091999B2 (de) 2014-01-09 2025-05-07 Hadasit Medical Research Services and Development Ltd. Verbesserte zellenzusammensetzungen und verfahren zur krebstherapie
CN120939216A (zh) 2014-01-13 2025-11-14 贝勒研究院 抗hpv和hpv相关的疾病的新疫苗
CN104774264B (zh) 2014-01-15 2018-09-14 上海易乐生物技术有限公司 抗人proBDNF单克隆抗体及其在疼痛中的作用
SI3101032T1 (sl) 2014-01-31 2019-02-28 Daiichi Sankyo Company, Limited Konjugat zdravila s protitelesci ANTI-HER2
EP3108255B1 (de) 2014-02-18 2020-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen zur behandlung von durch den nrp-1/obr-komplexsignalweg vermittelten krankheiten
WO2015124570A1 (en) 2014-02-18 2015-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of influenza a virus infection
EP2915543B1 (de) 2014-03-04 2018-05-09 Albert-Ludwigs-Universität Freiburg Aus Enterococcus abgeleitete Polypeptide und Verwendung davon zur Impfung und Erstellung von therapeutischen Antikörpern
WO2015140351A1 (en) 2014-03-21 2015-09-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing myelination
EP3122768A2 (de) 2014-03-27 2017-02-01 Yeda Research and Development Co. Ltd. T-zell-rezeptor-cdr3-peptide und -antikörper
SMT202500021T1 (it) 2014-04-10 2025-03-12 Daiichi Sankyo Co Ltd Metodo per produrre un coniugato anticorpo anti-her3-farmaco
CA2940585C (en) 2014-04-15 2023-08-08 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Differential diagnosis of eczema and psoriasis
EP3134546A4 (de) 2014-04-24 2017-12-06 Dana-Farber Cancer Institute, Inc. Tumorsuppressor und onkogene biomarker zur vorhersage der anti-immun-checkpoint-inhibitorreaktion
MY186711A (en) 2014-04-25 2021-08-12 Pf Medicament Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
RU2685259C2 (ru) 2014-04-25 2019-04-17 Пьер Фабр Медикамент Конъюгат антитела и лекарственного средства и его применение для лечения рака
RS61379B1 (sr) 2014-04-25 2021-02-26 Pf Medicament Antitelo na igf-1r i njegova upotreba kao usmerenog nosioca za lečenje kancera
SG11201608772UA (en) 2014-04-27 2016-11-29 Ccam Biotherapeutics Ltd Humanized antibodies against ceacam1
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
EP3160493A4 (de) 2014-06-26 2018-04-11 Yale University Zusammensetzungen und verfahren zur renalaseregulierung bei der behandlung von erkrankungen und störungen
CN112979828B (zh) 2014-07-17 2025-04-29 恺兴生命科技(上海)有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
WO2016011383A1 (en) 2014-07-17 2016-01-21 The Trustees Of The University Of Pennsylvania Methods for using exosomes to monitor transplanted organ status
EP3171896A4 (de) 2014-07-23 2018-03-21 Mayo Foundation for Medical Education and Research Abzielung auf dna-pkcs und b7-h1 zur behandlung von krebs
CN107074937B (zh) 2014-07-29 2021-07-27 神经免疫控股公司 人源抗亨廷顿蛋白(htt)抗体及其用途
AU2015326911C1 (en) 2014-09-30 2025-12-18 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (DPRs) antibody
WO2016054598A2 (en) 2014-10-03 2016-04-07 Massachusetts Institute Of Technology Antibodies that bind ebola glycoprotein and uses thereof
AU2015328411C1 (en) 2014-10-06 2022-03-03 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
CN113230384A (zh) 2014-10-09 2021-08-10 丹娜法伯癌症研究院 用于治疗免疫失调的多次-可变il-2剂量方案
EP3220900B1 (de) 2014-11-21 2020-09-23 University of Maryland, Baltimore Systeme zur gezielten strukturspezifischen partikelabgabe
US20170319661A1 (en) 2014-12-03 2017-11-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and Pharmaceutical Compositions Using Orexins (OXA, OXB) for the Treatment of Prostate Cancers
EP3256148A1 (de) 2015-02-12 2017-12-20 INSERM - Institut National de la Santé et de la Recherche Médicale Verfahren zur vorhersage der empfindlichkeit eines patienten mit bösartiger hämatologischer erkrankung auf chemotherapiebehandlung und verfahren zur behandlung solcher einer erkrankung
EP3265825A4 (de) 2015-03-06 2018-08-08 Dana-Farber Cancer Institute, Inc. Pd-l2-biomarker zur vorhersage von pd-1-weg-inhibitor-reaktionen bei ösophagogastrischem krebs
EP3067062A1 (de) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Kombination von tasquinimod oder einem pharmazeutisch zulässigen salz davon und pd1 und/oder pdl1-hemmer zur verwendung als medikament
CN108368169A (zh) 2015-03-18 2018-08-03 约翰霍普金斯大学 靶向钾通道kcnk9的新的单克隆抗体抑制剂
EP3273981B1 (de) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Verfahren und pharmazeutische zusammensetzung zur verwendung bei der behandlung von diabetes
EP3277309A1 (de) 2015-04-03 2018-02-07 Alienor Farma Monoklonaler antikörper gegen menschliches l1-orf2-protein und verfahren zur früherkennung von transformierenden zellen in präneoplastischem gewebe eines menschen
EP3283108B1 (de) 2015-04-13 2020-10-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Pn-1 inhibitoren zur verwendung zur behandlung von hämorragische erkrankung
US20180298104A1 (en) 2015-04-22 2018-10-18 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of th17 mediated diseases
EP3303392B1 (de) 2015-06-01 2020-08-05 Medigene Immunotherapies GmbH Verfahren zur erzeugung von antikörpern gegen t-zellrezeptor
EP3303389A1 (de) 2015-06-01 2018-04-11 Medigene Immunotherapies GmbH T-zell-rezeptor-spezifische antikörper
CA2987857A1 (en) 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh T cell receptor library
WO2016205738A2 (en) 2015-06-19 2016-12-22 Cytrx Corporation Delivery systems for controlled drug release
US20180161429A1 (en) 2015-06-26 2018-06-14 Beth Israel Deaconess Medical Center Inc. Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
US11173213B2 (en) 2015-06-29 2021-11-16 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
MY188405A (en) 2015-08-05 2021-12-08 Janssen Biotech Inc Anti-cd154 antibodies and methods of using them
EP3347380B1 (de) 2015-09-11 2024-09-25 Nascent Biotech, Inc. Verbesserte abgabe von medikamenten an das gehirn
WO2017046335A1 (en) 2015-09-18 2017-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) T cell receptors (tcr) and uses thereof for the diagnosis and treatment of diabetes
US10647752B2 (en) 2015-09-22 2020-05-12 Inserm (Institut National De La Santé Et De La Recherche Medicale) Polypeptides capable of inhibiting the binding between leptin and Neuropilin-1
IL288784B2 (en) 2015-09-24 2023-10-01 Daiichi Sankyo Co Ltd Antibodies against GARP, nucleotides encoding them, and vectors, cells and preparations containing them, methods for their preparation and uses thereof
JP2018529351A (ja) 2015-09-30 2018-10-11 ヤンセン バイオテツク，インコーポレーテツド ヒトｃｄ４０に特異的に結合するアンタゴニスト抗体及び使用方法
JP6857360B2 (ja) 2015-10-08 2021-04-14 国立大学法人東海国立大学機構 キメラ抗原受容体を発現する遺伝子改変ｔ細胞の調製方法
EP3362093A4 (de) 2015-10-13 2019-05-08 Technion Research & Development Foundation Limited Heparanase-neutralisierende monoklonale antikörper
WO2017064302A1 (en) 2015-10-16 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
CA3002765C (en) 2015-10-26 2023-02-28 Pierre Fabre Medicament Composition for the treatment of igf-1r expressing cancer
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
ITUB20155272A1 (it) 2015-11-02 2017-05-02 Scuola Normale Superiore Intracellular antibody
MA43186B1 (fr) 2015-11-03 2022-03-31 Janssen Biotech Inc Anticorps se liant spécifiquement à pd-1 et leurs utilisations
US20180320136A1 (en) 2015-11-03 2018-11-08 GlycoMimitics, Inc. Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
ITUB20155097A1 (it) 2015-11-05 2017-05-05 Biouniversa Srl Anticorpi umanizzati anti-BAG3
US10829562B2 (en) 2015-12-10 2020-11-10 Katholieke Universiteit Leuven Haemorrhagic disorder due to ventricular assist device
MA44072A (fr) 2015-12-17 2018-10-24 Janssen Biotech Inc Anticorps se liant spécifiquement à hla-dr et leurs utilisations
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
EP3889253A1 (de) 2015-12-23 2021-10-06 Medigene Immunotherapies GmbH Zusammensetzung aus dendritischen zellen
US11789021B2 (en) 2015-12-31 2023-10-17 Progastrine Et Cancers S.À R.L. Compositions and methods for detecting and treating esophageal cancer
CA3009740A1 (en) 2015-12-31 2017-07-06 Progastrine Et Cancers S.A R.L. Compositions and methods for detecting and treating gastric cancer
EA037015B1 (ru) 2015-12-31 2021-01-27 Прогастрин Э Кансер С.А Р.Л. Применение и способ для профилактики или лечения рака яичников с использованием композиции, содержащей прогастринсвязывающее антитело
EP3202788A1 (de) 2016-02-05 2017-08-09 MediaPharma S.r.l. Endosialinbindender antikörper
EP3205663A1 (de) 2016-02-15 2017-08-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Mittel und verfahren zur hemmung der genexpression
EP3416688B1 (de) 2016-02-15 2022-08-17 INSERM - Institut National de la Santé et de la Recherche Médicale Apelin zur verwendung bei der behandlung von postoperativer kognitiver dysfunktion
CA3015619A1 (en) 2016-03-01 2017-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
WO2017153432A1 (en) 2016-03-07 2017-09-14 Pierre Fabre Medicament A new universal method to capture and analyze adcs for characterization of drug distribution and the drug-to-antibody ratio in biological samples
US11921116B2 (en) 2016-03-09 2024-03-05 Memorial Sloan Kettering Cancer Center Enigma and CDH18 as companion diagnostics for CDK4 inhibitors
EP3779447B1 (de) 2016-03-15 2023-02-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur aktivierung der antitumoralen cd8+t-zellantwort eines krebspatienten
WO2017158396A1 (en) 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
WO2017162604A1 (en) 2016-03-21 2017-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and treatment of solar lentigo
RU2744959C2 (ru) 2016-03-23 2021-03-17 Мэбспейс Байосайнсиз (Сучжоу) Ко., Лтд Новые анти-pd-l1 антитела
KR102744951B1 (ko) 2016-03-28 2024-12-23 인사이트 코포레이션 Tam 억제제로서 피롤로트리아진 화합물
ITUA20162242A1 (it) 2016-04-01 2017-10-01 St Biochimico Italiano Giovanni Lorenzini Spa Un nuovo anticorpo anti-erbb2
KR102354845B1 (ko) 2016-04-18 2022-01-24 파론 파머수티컬스 오와이 인간화 항 clever-1 항체 및 이의 용도
ES2941693T3 (es) 2016-05-03 2023-05-24 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de lesiones tisulares
CN115873904A (zh) 2016-05-11 2023-03-31 美国安进公司 使用谷氨酰胺合成酶基因内互补载体直接选择表达高水平异聚蛋白的细胞
EP3458093A1 (de) 2016-05-20 2019-03-27 Christoph Karl Pharmazeutische zusammensetzungen mit anti-rankl-antikörpern, kalzium und vitamin d, geeignet zur behandlung und/oder prophylaxe von erkrankungen des knochenstoffwechsels und von therapiebedingten nebenwirkungen wie hypokalzämien
WO2017202814A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of neuropathological disorders characterized by a loss of cortical neurons
EP3464357A1 (de) 2016-05-24 2019-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen zur behandlung von bakteriellen lungeninfektionen
CA3026778A1 (en) 2016-06-07 2017-12-14 Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft Chimeric antigen receptor and car-t cells that bind bcma
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
ES2883182T3 (es) 2016-07-06 2021-12-07 Prothena Biosciences Ltd Ensayo para la detección de alfa-sinucleína total y fosforilada en S129
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
US20190330318A1 (en) 2016-07-25 2019-10-31 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
WO2018019990A1 (en) 2016-07-28 2018-02-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of treatement of cancer disease by targetting tumor associated macrophage
MA45941A (fr) 2016-08-12 2019-06-19 Janssen Biotech Inc Anticorps de membres de la superfamille anti-tnfr modifiés par fc ayant une activité agoniste améliorée et leurs procédés d'utilisation
US10669344B2 (en) 2016-08-12 2020-06-02 Janssen Biotech, Inc. Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions
ES3033182T3 (en) 2016-09-20 2025-07-31 Dana Farber Cancer Inst Inc Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators
EP3524267A4 (de) 2016-10-07 2020-06-10 Daiichi Sankyo Company, Limited Therapie für arzneimittelresistenten krebs durch verabreichung von anti-her2-antikörper/arzneimittel-konjugat
JPWO2018070390A1 (ja) 2016-10-12 2019-08-22 第一三共株式会社 抗ｒｏｂｏ４抗体と他剤を含む組成物
SG10201912925SA (en) 2016-10-13 2020-02-27 Massachusetts Inst Technology Antibodies that bind zika virus envelope protein and uses thereof
IT201600111877A1 (it) 2016-11-07 2018-05-07 Biouniversa Srl Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use
EP3543337B1 (de) 2016-11-18 2022-04-20 Astellas Pharma Inc. Neuartiges fab-fragment eines anti-humanen muc1-antikörpers
EP3552626A4 (de) 2016-12-12 2020-06-10 Daiichi Sankyo Company, Limited Kombination aus antikörper-wirkstoff-konjugat und immun-checkpoint-inhibitor
WO2018110555A1 (ja) 2016-12-13 2018-06-21 アステラス製薬株式会社 抗ヒトｃｄ７３抗体
US10836818B2 (en) 2016-12-15 2020-11-17 The National Institute For Biotechnology I Anti-PCNA monoclonal antibodies and use thereof
BR112019012901A2 (pt) 2016-12-22 2020-01-07 Daiichi Sankyo Company, Limited Anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo e uma molécula que se ligue ao cd3 humano e ao cd3 de macaco cinomolgo, composição farmacêutica, e, molécula
US20180179490A1 (en) 2016-12-27 2018-06-28 Miltenyi Biotec Gmbh CELL COMPOSITION DEPLETED FROM TCRab and CD45RA POSITIVE CELLS
US11773182B2 (en) 2017-01-05 2023-10-03 The Johns Hopkins University Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)
CN110382535A (zh) 2017-01-17 2019-10-25 第一三共株式会社 抗-gpr20抗体以及抗-gpr20抗体-药物缀合物
WO2018140510A1 (en) 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders
WO2018147245A1 (ja) 2017-02-07 2018-08-16 第一三共株式会社 抗ｇｐｒｃ５ｄ抗体及び該抗体を含む分子
EP3363459A1 (de) 2017-02-17 2018-08-22 Alexander Klimka Polypeptid-epitope von s. aureus und entsprechende monoklonale antikörper zur behandlung von infektionen und immundiagnose
US11623953B2 (en) 2017-02-27 2023-04-11 Caerus Therapeutics, Inc. Antibody constructs and methods of treating cancer
AU2018227146B2 (en) 2017-02-28 2025-04-03 Daiichi Sankyo Company, Limited Method for treating EGFR-TKI-resistant non-small cell lung cancer by administration of anti-HER3 antibody-drug conjugate
WO2018166495A1 (en) 2017-03-15 2018-09-20 Tsinghua University Novel anti-trkb antibodies
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
TWI782000B (zh) 2017-03-30 2022-11-01 日商第一三共股份有限公司 抗ｇｐｒ２０抗體、其製造方法及其應用
KR102600130B1 (ko) 2017-03-30 2023-11-08 이씨에스-프로가스트린 에스에이 폐암을 검출하기 위한 조성물 및 방법
SG11201908998XA (en) 2017-03-30 2019-10-30 Progastrine Et Cancers S A R L Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule
US10722589B2 (en) 2017-04-03 2020-07-28 Covagen Ag FGFR3 binding molecules
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
WO2018189403A1 (en) 2017-04-14 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancer
WO2018209301A1 (en) 2017-05-11 2018-11-15 Cytodyn Inc. Methods for treating or preventing graft-versus-host disease involving the administration of anti-ccr5 receptor agents
TW202530219A (zh) 2017-05-15 2025-08-01 日商第一三共股份有限公司 抗體－藥物結合物之製造方法
MX2019014577A (es) 2017-06-05 2020-07-29 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y metodos de uso.
US11820822B2 (en) 2017-06-06 2023-11-21 Dana-Farber Cancer Institute, Inc. Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways
CA3067747A1 (en) 2017-06-23 2018-12-27 Mabylon Ag Anti-allergen antibodies
US20210145828A1 (en) 2017-06-29 2021-05-20 Rutgers, The State University Of New Jersey Compositions And Methods Targeting G12 Signaling For Bronchodilator Therapy
WO2019004487A1 (ja) 2017-06-30 2019-01-03 国立大学法人北海道大学 成長障害を生じない小児骨粗鬆症治療薬
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
US11464845B2 (en) 2017-07-21 2022-10-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neisseria meningitidis immunogenic compositions
WO2019022187A1 (ja) 2017-07-27 2019-01-31 第一三共株式会社 抗ｃｄ１４７抗体
US20210024623A1 (en) 2017-07-28 2021-01-28 Intrepida Bio, Inc. Anti-bag3 antibodies as therapeutic reagent in cardiovascular disease
WO2019025299A1 (en) 2017-07-31 2019-02-07 F. Hoffmann-La Roche Ag METHOD OF HUMANIZATION BASED ON THREE DIMENSIONAL STRUCTURE
EP3444272A1 (de) 2017-08-17 2019-02-20 International-Drug-Development-Biotech Behandlung von ck8-positivem krebs in verbindung mit dem k-ras-genstatus
CN111094349B (zh) 2017-08-23 2025-02-07 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 嵌合抗原受体和结合cxcr5的car-t细胞
CA3073383C (en) 2017-08-23 2023-10-31 Daiichi Sankyo Company, Limited Antibody-drug conjugate preparation and lyophilization for same
JP7366745B2 (ja) 2017-08-31 2023-10-23 第一三共株式会社 抗体－薬物コンジュゲートの改良製造方法
WO2019044946A1 (ja) 2017-08-31 2019-03-07 第一三共株式会社 抗体－薬物コンジュゲートの新規製造方法
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
AU2018342471B2 (en) 2017-09-27 2023-08-24 Incyte Corporation Salts of pyrrolotriazine derivatives useful as TAM inhibitors
CA3126646A1 (en) 2017-09-29 2019-04-04 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
US20200345800A1 (en) 2017-10-03 2020-11-05 Tokyo Metropolitan Institute Of Medical Science Medication for influenza
KR102818021B1 (ko) 2017-10-05 2025-06-10 다이이찌 산쿄 가부시키가이샤 세포 상해성 t 세포 고갈용 조성물
KR101966362B1 (ko) 2017-10-20 2019-04-05 주식회사 녹십자 항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
CN111587123A (zh) 2017-11-09 2020-08-25 品通治疗有限公司 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物
US11572373B2 (en) 2017-11-30 2023-02-07 Ladrx Corporation Maytansinoid-based drug delivery systems
NZ764948A (en) 2017-11-30 2024-08-30 Ladrx Corp Albumin-binding prodrugs of auristatin e derivatives
WO2019106126A1 (en) 2017-12-01 2019-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Mdm2 modulators for the diagnosis and treatment of liposarcoma
TWI763956B (zh) 2017-12-05 2022-05-11 盧森堡商前胃泌激素及癌症有限公司 治療癌症的抗前胃泌激素抗體與免疫療法之組合療法
WO2019121872A1 (en) 2017-12-20 2019-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of liver cancer
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
TW201940881A (zh) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
US11834487B2 (en) 2018-02-12 2023-12-05 Hadasit Medical Research Services & Development Ltd. Modulation of SLAMF6 splice variants for cancer therapy
WO2019158512A1 (en) 2018-02-13 2019-08-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prognosis and the treatment of glioblastoma
WO2019166499A1 (en) 2018-02-27 2019-09-06 Ecs-Progastrin Sa Progastrin as a biomarker for immunotherapy
CA3092470A1 (en) 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
WO2019168897A2 (en) 2018-02-28 2019-09-06 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
US12234280B2 (en) 2018-03-05 2025-02-25 Janssen Pharmaceutica Nv Anti-PHF-tau antibodies and uses thereof
AU2019231380A1 (en) 2018-03-05 2020-09-24 Daiichi Sankyo Company, Limited Pharmaceutical composition for treating or preventing heterotopic ossification
WO2019170147A1 (zh) 2018-03-09 2019-09-12 科济生物医药（上海）有限公司 用于治疗肿瘤的方法和组合物
WO2019185683A1 (en) 2018-03-28 2019-10-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
EP3773658A4 (de) 2018-04-06 2022-04-27 Dana-Farber Cancer Institute, Inc. Kir3dl3 als hla2-rezeptor, anti-hhla2-antikörper und ihre verwendungen
EP3775908A1 (de) 2018-04-13 2021-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur vorhersage des ergebnisses und der behandlung von patienten mit prostatakrebs oder brustkrebs
US12054529B2 (en) 2018-04-20 2024-08-06 Medizinische Hochschule Hannover Chimeric antigen receptor and CAR-T cells that bind a herpes virus antigen
WO2019207066A1 (en) 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of sjögren's syndrome
WO2019211369A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
WO2019211370A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
JP2021522801A (ja) 2018-05-09 2021-09-02 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド ヒトネクチン４に特異的な抗体
JOP20200285A1 (ar) 2018-05-11 2020-11-09 Astellas Pharma Inc حمض نووي لعلاج حساسية العث
BR112020023031A2 (pt) 2018-05-11 2021-02-09 Astellas Pharma Inc. ácido nucleico para tratar alergia a crustáceo
JP7360766B2 (ja) 2018-05-17 2023-10-13 アステラス製薬株式会社 抗ヒトＭＵＣ１抗体Ｆａｂフラグメント、ペプチドリンカー及び／又は配位子を含む複合体
WO2019222677A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
US11866499B2 (en) 2018-05-24 2024-01-09 Janssen Biotech, Inc. Monospecific and multispecific anti-TMEFF2 antibodies and their uses
AU2019274657A1 (en) 2018-05-24 2020-12-10 Janssen Biotech, Inc. PSMA binding agents and uses thereof
EP3802608B1 (de) 2018-05-24 2025-04-30 Janssen Biotech, Inc. Anti-cd3-antikörper und verwendungen davon
KR20250105480A (ko) 2018-05-28 2025-07-08 다이이찌 산쿄 가부시키가이샤 항 her2 항체-약물 콘쥬게이트 투여에 의한 her2 변이암의 치료
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
TWI833761B (zh) 2018-05-31 2024-03-01 日商第一三共股份有限公司 抗人類ｔｌｒ７抗體以及其製造方法及用途
BR112020024351A2 (pt) 2018-06-01 2021-02-23 Novartis Ag moléculas de ligação contra bcma e usos das mesmas
KR102848349B1 (ko) 2018-06-04 2025-08-21 바이오젠 엠에이 인코포레이티드 감소된 효과기 기능을 갖는 항-ｖｌａ-4 항체
WO2019234099A1 (en) 2018-06-06 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
IL279455B1 (en) 2018-06-20 2025-09-01 Incyte Corp ANTI-PD-1 ANTIBODIES AND THEIR USES
US12129298B2 (en) 2018-06-21 2024-10-29 Daiichi Sankyo Company, Limited Compositions including CD3 antigen binding fragments and uses thereof
ES3031110T3 (en) 2018-06-29 2025-07-04 Incyte Corp Formulations of an axl/mer inhibitor
WO2020007898A1 (en) 2018-07-04 2020-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating brain injury or neurodegenerative disease
AU2019297361B2 (en) 2018-07-05 2024-06-27 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
WO2020022363A1 (ja) 2018-07-25 2020-01-30 第一三共株式会社 抗体－薬物コンジュゲートの効果的な製造方法
EP3831408A4 (de) 2018-07-27 2021-11-17 Osaka University Zusammensetzung zur hemmung von alterung, vorbeugung, verbesserung oder behandlung von altersbedingten krankheiten oder verlängerung der lebensdauer
TWI846717B (zh) 2018-07-27 2024-07-01 日商第一三共股份有限公司 辨識抗體-藥物結合物之藥物部位的蛋白質
CN112805036A (zh) 2018-07-31 2021-05-14 第一三共株式会社 通过施用抗体-药物缀合物对转移性脑肿瘤的治疗
EP3834843A4 (de) 2018-08-06 2022-05-11 Daiichi Sankyo Company, Limited Kombination aus antikörper-wirkstoff-konjugat und tubulininhibitor
IL281247B2 (en) 2018-09-06 2025-01-01 Daiichi Sankyo Co Ltd Novel cyclic dinucleotide derivatives and their antibody-drug conjugates
JPWO2020059772A1 (ja) 2018-09-20 2021-08-30 第一三共株式会社 抗ｈｅｒ３抗体−薬物コンジュゲート投与によるｈｅｒ３変異がんの治療
US12319731B2 (en) 2018-09-21 2025-06-03 Institute Of Science Tokyo Human monoclonal antibody binding specifically to human HMGB1, and pharmaceutical composition for treating or preventing Alzheimer's disease containing said human monoclonal antibody
EP3856258B1 (de) 2018-09-27 2024-07-31 Pierre Fabre Medicament Sulfomaleimidbasierte linker und zugehörige konjugate
CN113164558A (zh) 2018-09-28 2021-07-23 皮埃尔法布雷医药公司 用于治疗癌症的新型免疫细胞因子
JP7374544B2 (ja) 2018-10-10 2023-11-07 アステラス製薬株式会社 標識部－抗ヒト抗体Ｆａｂフラグメント複合体を含む医薬組成物
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
EP3867269A1 (de) 2018-10-18 2021-08-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Kombination aus einem big-h3-antagonisten und einem immun-checkpoint-inhibitor zur behandlung von soliden tumoren
WO2020090892A1 (ja) 2018-10-31 2020-05-07 アステラス製薬株式会社 抗ヒトＦｎ１４抗体
WO2020092736A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US12264189B2 (en) 2018-10-31 2025-04-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2020099235A1 (en) 2018-11-12 2020-05-22 Mediapharma S.R.L. Bispecific antibodies directed against human 90k and either endosialin or her3
SG11202104993SA (en) 2018-11-14 2021-06-29 Daiichi Sankyo Co Ltd Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate
US12227548B2 (en) 2018-11-19 2025-02-18 Dana-Farber Cancer Institute, Inc. Use of IRE1α-XBP1 signaling pathway biomarkers for modulating immune responses
EA202191641A1 (ru) 2018-12-11 2021-09-13 Дайити Санкио Компани, Лимитед Комбинация конъюгата антитело-лекарственное средство с ингибитором parp
AU2019407426A1 (en) 2018-12-21 2021-07-22 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
JP7737143B2 (ja) 2018-12-21 2025-09-10 エイム・イムノテック・インコーポレイテッド がん治療のための組成物および方法
IL284623B2 (en) 2019-01-07 2025-04-01 Astellas Pharma Inc A conjugate containing a ligand, a spacer, a peptide linker, and a biomolecule
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
KR20210117277A (ko) 2019-01-13 2021-09-28 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 인간 넥틴-2에 특이적인 항체
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US20220125754A1 (en) 2019-01-29 2022-04-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Treating the causative agent in adhesiogenesis
SG11202108560RA (en) 2019-02-13 2021-09-29 Brigham & Womens Hospital Inc Anti-peripheral lymph node addressin antibodies and uses thereof
WO2020178193A1 (en) 2019-03-01 2020-09-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment of sarcoidosis
EP3938400B1 (de) 2019-03-11 2025-07-30 Memorial Sloan Kettering Cancer Center Cd22-antikörper und verfahren zur verwendung davon
US20220154153A1 (en) 2019-03-22 2022-05-19 Université de Paris New inhibitors of lrrk2/pp1 interaction
TWI856078B (zh) 2019-03-25 2024-09-21 日商第一三共股份有限公司 抗體–吡咯并苯二氮呯衍生物結合物、其製造方法及其用途
US20220154191A1 (en) 2019-03-25 2022-05-19 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Enhancement of cytolytic t-cell activity by inhibiting ebag9
BR112021017616A2 (pt) 2019-03-25 2021-11-09 Daiichi Sankyo Co Ltd Conjugado de derivado de anticorpo anti-her2-pirrolobenzodiazepina
CN113631191B (zh) 2019-03-27 2024-09-27 第一三共株式会社 抗体－吡咯并苯并二氮杂卓衍生物偶联物与parp抑制剂的组合
CN113660954B (zh) 2019-04-01 2025-01-14 凯奥目生物科学株式会社 癌症治疗用药物
EP3946626A1 (de) 2019-04-02 2022-02-09 Kenjockety Biotechnology, Inc. Multispezifische antikörper und zusammensetzungen, reagenzien, kits und verfahren dazu
US11591395B2 (en) 2019-04-19 2023-02-28 Janssen Biotech, Inc. Methods of treating prostate cancer with an anti-PSMA/CD3 antibody
US20220289854A1 (en) 2019-04-30 2022-09-15 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
SG11202111130SA (en) 2019-04-30 2021-11-29 Senti Biosciences Inc Chimeric receptors and methods of use thereof
WO2020229546A1 (en) 2019-05-14 2020-11-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof
AU2020282792B2 (en) 2019-05-28 2025-12-04 Banner Health ApoE antibodies, fusion proteins and uses thereof
WO2020240467A1 (en) 2019-05-29 2020-12-03 Daiichi Sankyo Company, Limited Dosage of an antibody-drug conjugate
TW202115114A (zh) 2019-06-24 2021-04-16 瑞士商諾華公司 針對靶向ｂ細胞成熟抗原的多特異抗體之給藥方案及組合療法
MX2022001049A (es) 2019-07-26 2022-05-03 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos.
JP7668013B2 (ja) 2019-07-26 2025-04-24 学校法人 埼玉医科大学 Ａｌｋ２／ａｃｖｒ１の細胞外領域を認識する抗体
WO2021019706A1 (ja) 2019-07-31 2021-02-04 国立大学法人信州大学 Ｃａｒ発現免疫細胞を含む細胞集団の製造方法
CN114502196A (zh) 2019-08-01 2022-05-13 因赛特公司 Ido抑制剂的给药方案
CN114502594A (zh) 2019-08-02 2022-05-13 西托戴恩股份有限公司 牵涉施用抗-ccr5受体试剂的用于治疗或预防癌症的方法
EP4013510A1 (de) 2019-08-12 2022-06-22 Biond Biologics Ltd. Antikörper gegen ilt2 und verwendung davon
EP3792632A1 (de) 2019-09-16 2021-03-17 Vito NV Immuntherapiemarker
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
WO2021058744A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of müllerian inhibiting substance inhibitors for treating cancer
CN114746119A (zh) 2019-09-27 2022-07-12 詹森生物科技公司 抗-ceacam抗体及其用途
WO2021079958A1 (ja) 2019-10-25 2021-04-29 第一三共株式会社 抗ｇａｒｐ抗体と免疫調節剤の組み合わせ
MX2022005904A (es) 2019-11-15 2022-09-07 Pliant Therapeutics Inc Composiciones y metodos para la activacion de integrinas.
MX2022005980A (es) 2019-11-18 2022-09-07 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos.
AU2020399790B2 (en) * 2019-12-10 2025-06-26 CCOA Therapeutics (Hangzhou) Co., Ltd. Humanized anti-glycoprotein Ib alpha (GPIbalpha) antibodies
US11396541B2 (en) 2019-12-20 2022-07-26 Novarock Biotherapeutics, Ltd. Anti-interleukin-23 P19 antibodies and methods of use thereof
EP4085060A1 (de) 2020-01-03 2022-11-09 Incyte Corporation Kombinationstherapie mit a2a/a2b- und pd-1/pd-l1-inhibitoren
WO2021140173A1 (en) 2020-01-10 2021-07-15 Biouniversa S.R.L. Methods and uses for treating fibrotic solid tumors with bags inhibitors
US20230075965A1 (en) 2020-01-24 2023-03-09 Constantine S. Mitsiades Uses of biomarkers for improving immunotherapy
EP4100525A1 (de) 2020-02-05 2022-12-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren zur behandlung von krebserkrankungen durch targeting eines epigenetischen faktors
AU2021219948A1 (en) 2020-02-12 2022-10-06 Janssen Pharmaceutica Nv FGFR tyrosine kinase inhibitors and anti-PD1 agents for the treatment of urothelial carcinoma
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
JP2023516028A (ja) 2020-02-28 2023-04-17 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 多重特異性抗体を介したトランスフォーミング増殖因子ベータスーパーファミリーシグナル伝達の選択的調節
IL295780A (en) 2020-03-03 2022-10-01 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
KR20220151630A (ko) 2020-03-06 2022-11-15 다이이찌 산쿄 가부시키가이샤 신규 고리형 디뉴클레오티드 유도체를 포함하는 항체 약물 컨쥬게이트
AU2021230385A1 (en) 2020-03-06 2022-09-22 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
EP4118112A1 (de) 2020-03-10 2023-01-18 Massachusetts Institute of Technology Zusammensetzungen und verfahren zur immuntherapie von npm1c-positivem krebs
UY40280A (es) 2020-03-13 2023-07-31 Janssen Biotech Inc Dominios de unión a antígeno que se unen a la proteina cd33 de la superficie de células mieloides
US11045546B1 (en) 2020-03-30 2021-06-29 Cytodyn Inc. Methods of treating coronavirus infection
CA3173263A1 (en) 2020-03-30 2021-10-07 Yasuhiro Matsumura Antibody drug conjugate
EP3889183A1 (de) 2020-04-01 2021-10-06 Pierre Fabre Medicament Proteinkomplex mit einem immunzytokin
BR112022020232A2 (pt) 2020-04-06 2022-12-13 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticorpos contra nkp46 e construtos dos mesmos para o tratamento de cânceres e infecções
CN115397860B (zh) 2020-05-14 2025-06-13 江苏恒瑞医药股份有限公司 抗cd25抗体、其抗原结合片段及其医药用途
EP4153192B8 (de) 2020-05-19 2024-09-04 Institut Curie Antagonist des cd44/hyaluronsäure-wegs zur verwendung in einem verfahren zur behandlung des zytokinfreisetzungssyndroms
CN116249714A (zh) 2020-05-27 2023-06-09 詹森生物科技公司 包含cd3抗原结合结构域的蛋白质及其用途
KR20230029671A (ko) 2020-05-27 2023-03-03 아리아리스 테라퓨틱스, 인크. 항-인간 nr1 항체 유도체
US20230192902A1 (en) 2020-06-04 2023-06-22 Kenjockety Biotechnology, Inc. Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
IL299368A (en) 2020-06-24 2023-02-01 Astrazeneca Uk Ltd A combination of an antibody-drug conjugate and an ATR inhibitor
TW202216207A (zh) 2020-06-24 2022-05-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及cdk9抑制劑之組合
EP4171651A1 (de) 2020-06-24 2023-05-03 AstraZeneca UK Limited Kombination aus antikörper-wirkstoff-konjugat und atm-inhibitor
WO2021260139A1 (en) 2020-06-25 2021-12-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of treatment and diagnostic of pathological conditions associated with intense stress
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
BR112023000711A2 (pt) 2020-07-17 2023-01-31 Daiichi Sankyo Co Ltd Método para produzir uma composição de conjugado de anticorpo-fármaco, e, composição de conjugado de anticorpo-fármaco
KR20230042055A (ko) 2020-07-20 2023-03-27 다이이찌 산쿄 가부시키가이샤 항 her2 항체-약물 콘주게이트와 her 이량체화 저해제의 조합
JP2023536818A (ja) 2020-07-29 2023-08-30 ヤンセン バイオテツク，インコーポレーテツド Ｈｌａ－ｇ抗原結合ドメインを含むタンパク質及びそれらの使用
RU2764216C1 (ru) * 2020-08-10 2022-01-14 Федеральное государственное бюджетное образовательное учреждение высшего образования "Чувашский государственный университет имени И.Н. Ульянова" Способ лечения гломерулонефритов с нефротическим синдромом рецидивирующего течения
BR112023002301A2 (pt) 2020-08-12 2023-10-03 Biond Biologics Ltd Anticorpos contra ilt2 e uso dos mesmos
AU2021334107A1 (en) 2020-08-24 2023-03-02 Charité - Universitätsmedizin Berlin A chimeric antigen receptor construct encoding a checkpoint inhibitory molecule and an immune stimulatory cytokine and car-expressing cells recognizing CD44v6
US20230321242A1 (en) 2020-08-24 2023-10-12 Charité - Universitätsmedizin Berlin Chimeric antigen receptor (car)-expressing cells recognizing cea
AU2021337687A1 (en) 2020-09-04 2023-03-23 CSPC Megalith Biopharmaceutical Co., Ltd., Nectin-4 antibodies and uses thereof
US20230340149A1 (en) 2020-09-07 2023-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of treatment of inflammatory bowel diseases
JP2023545359A (ja) 2020-09-12 2023-10-30 アストラゼネカ・ユーケイ・リミテッド 抗ｈｅｒ２抗体－薬物複合体治療のためのスコアリング方法
KR20230083296A (ko) 2020-10-05 2023-06-09 치오메 바이오사이언스 가부시키가이샤 암 치료용 의약
KR20230084163A (ko) 2020-10-09 2023-06-12 아스트라제네카 유케이 리미티드 항체-약물 접합체와 parp1 선택적 억제제의 조합
US11926667B2 (en) 2020-10-13 2024-03-12 Janssen Biotech, Inc. Bioengineered T cell mediated immunity, materials and other methods for modulating cluster of differentiation IV and/or VIII
US20230416346A1 (en) 2020-10-21 2023-12-28 INSERM (Institut National de la Santé et de la Recherche Médicale) C-terminal sparc fragments for treating cancer
JP2023548034A (ja) 2020-10-22 2023-11-15 ヤンセン バイオテツク，インコーポレーテツド デルタ様リガンド３（ｄｌｌ３）抗原結合ドメインを含むタンパク質及びその使用
WO2022097090A1 (en) 2020-11-05 2022-05-12 Novartis Ag Dosing regimen for combination therapies with multispecific antibodies targeting b-cell maturation antigen and gamma secretase inhibitors
WO2022096633A1 (en) 2020-11-06 2022-05-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and treating polycystic ovary syndrome (pcos)
AU2021378152A1 (en) 2020-11-11 2023-06-22 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPα ANTIBODY
US20230398230A1 (en) 2020-11-12 2023-12-14 Daiichi Sankyo Company, Limited Treatment of mesothelioma by administration of anti-b7-h3 antibody-drug conjugate
CA3200860A1 (en) 2020-11-16 2022-05-19 Astellas Pharma Inc. Anti-tspan8/anti-cd3 bispecific antibody and anti-tspan8 antibody
EP4251282A1 (de) 2020-11-27 2023-10-04 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren zur diagnose und überwachung von toxischer epidermaler nekrolyse
CA3203587A1 (en) 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
WO2022115120A1 (en) 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
JPWO2022124247A1 (de) 2020-12-09 2022-06-16
AU2021411952A1 (en) 2020-12-29 2023-08-10 Incyte Corporation Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
WO2022153212A1 (en) 2021-01-13 2022-07-21 Axon Neuroscience Se Antibodies neutralizing sars-cov-2
JP2024503658A (ja) 2021-01-13 2024-01-26 メモリアル スローン－ケタリング キャンサー センター 抗ｄｌｌ３抗体－薬物コンジュゲート
MX2023008261A (es) 2021-01-13 2023-09-12 Memorial Sloan Kettering Cancer Center Conjugado de anticuerpo-derivado de pirrolobenzodiazepina.
PE20240761A1 (es) 2021-01-28 2024-04-17 Janssen Biotech Inc Proteinas de union a psma y usos de estas
JP2024505049A (ja) 2021-01-29 2024-02-02 ノバルティス アーゲー 抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
TW202241454A (zh) 2021-02-01 2022-11-01 日商第一三共股份有限公司 抗體－免疫賦活化劑共軛物之新穎製造方法
CN116829591A (zh) 2021-02-11 2023-09-29 奈克汀治疗有限公司 针对cd112r的抗体及其用途
CA3208905A1 (en) 2021-02-12 2022-08-18 Boehringer Ingelheim International Gmbh Complement c3 antigen binding proteins
US20220378929A1 (en) 2021-02-25 2022-12-01 MediBoston Limted Anti-her2 antibody-drug conjugates and uses thereof
AU2022229805A1 (en) 2021-03-02 2023-09-21 Dana-Farber Cancer Institute, Inc. Methods of treating red blood cell disorders
EP4305064A1 (de) 2021-03-12 2024-01-17 Fibrosys S.r.l. Monoklonale antikörper zur behandlung von virusinfektionen
IL305816A (en) 2021-03-12 2023-11-01 Daiichi Sankyo Co Ltd Glycan and a method for preparing a medicine containing it
US12084501B2 (en) 2021-03-24 2024-09-10 Janssen Biotech, Inc. Proteins comprising CD3 antigen binding domains and uses thereof
TW202304986A (zh) 2021-03-24 2023-02-01 美商健生生物科技公司 靶向cd22及cd79b的抗體
BR112023019205A2 (pt) 2021-03-26 2023-10-24 Janssen Biotech Inc Anticorpos humanizados contra tau de filamento helicoidal pareado e usos dos mesmos
WO2022218998A1 (en) 2021-04-13 2022-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating hepatitis b and d virus infection
CA3215058A1 (en) 2021-04-14 2022-10-20 William James Jonathan Finlay Anti-cd122 antibodies and uses thereof
CN117222672A (zh) 2021-04-22 2023-12-12 安斯泰来制药株式会社 抗cldn4-抗cd137双特异性抗体
US20240280561A1 (en) 2021-06-08 2024-08-22 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
CN113361141B (zh) * 2021-07-11 2022-02-18 西南石油大学 一种dna图谱算法的改进试验方法
KR20240049342A (ko) 2021-08-27 2024-04-16 얀센 바이오테크 인코포레이티드 항-psma 항체 및 이의 용도
US20240390512A1 (en) 2021-09-15 2024-11-28 Daiichi Sankyo Company, Limited Methods of treating chemotherapy-resistant cancer with an antibody-drug conjugate
EP4401715A1 (de) 2021-09-17 2024-07-24 Institut Curie Bet-inhibitoren zur behandlung von pab1-defizientem krebs
US20250019455A1 (en) 2021-09-24 2025-01-16 Pharmaceutica Nv Proteins comprising cd20 binding domains, and uses thereof
WO2023052541A1 (en) 2021-09-30 2023-04-06 Imcheck Therapeutics Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
EP4420683A1 (de) 2021-10-18 2024-08-28 Daiichi Sankyo Company, Limited Anti-cd37-antikörper-wirkstoff-konjugat
AU2022378932A1 (en) 2021-10-27 2024-05-02 Assistance Publique Hopitaux De Marseille Butyrophilin (btn) 3a activating antibodies for use in methods for treating infectious disorders
EP4177266A1 (de) 2021-11-05 2023-05-10 Katholieke Universiteit Leuven Neutralisierende humane anti-sars-cov-2-antikörper
TW202329936A (zh) 2021-11-18 2023-08-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物與parp1選擇性抑制劑之組合
EP4433089A1 (de) 2021-11-19 2024-09-25 Institut Curie Verfahren zur behandlung von hrd-krebs und brca-assoziiertem krebs
US20250381241A1 (en) 2021-11-29 2025-12-18 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
WO2023099763A1 (en) 2021-12-03 2023-06-08 Institut Curie Sirt6 inhibitors for use in treating resistant hrd cancer
JP7235262B1 (ja) 2021-12-07 2023-03-08 国立大学法人大阪大学 抗体又はその抗原結合性断片
WO2023105528A1 (en) 2021-12-12 2023-06-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to ceacam1
AU2022420788A1 (en) 2021-12-22 2024-05-16 Boehringer Ingelheim International Gmbh Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
KR20240131370A (ko) 2021-12-22 2024-08-30 인사이트 코포레이션 항-cd19 항체 요법을 위한 치료 패러다임
US20250161305A1 (en) 2021-12-28 2025-05-22 Astrazeneca Uk Limited Combination of antibody-drug conjugate and rasg12c inhibitor
US20250064967A1 (en) 2021-12-28 2025-02-27 Astrazeneca Uk Limited Combination of antibody-drug conjugate and atr inhibitor
JPWO2023145844A1 (de) 2022-01-27 2023-08-03
WO2023152581A1 (en) 2022-02-09 2023-08-17 Janssen Biotech, Inc. Method of treating cancer with psmaxcd3 antibody
CN118804983A (zh) 2022-03-02 2024-10-18 第一三共株式会社 含Fc分子的制造方法
JP2025512250A (ja) 2022-03-02 2025-04-17 ハイデルべルク イミュノセラピューティクス ゲーエムベーハー 抗体または抗体Ｆｃ部分を含むＦｃ含有融合タンパク質を含む、ワクチン
US20250186602A1 (en) 2022-03-09 2025-06-12 Cured Inc. Humanized antibody that bonds to eva1 protein or functional fragment thereof, antibody-drug conjugate and chimeric antigen receptor
CA3243774A1 (en) 2022-03-15 2023-09-21 Yeda Research And Development Co. Ltd. Anti-Glucocorticoid-Induced TNFR-Related Protein (GITR) Antibodies and Their Uses
JP2025509564A (ja) 2022-03-16 2025-04-11 アストラゼネカ ユーケー リミテッド 抗ｔｒｏｐ２抗体－薬物コンジュゲート治療のためのスコアリング方法
US20250296968A1 (en) 2022-04-25 2025-09-25 Tokyo Metropolitan Institute Of Medical Science Variant neurodegenerative disease-associated protein
CA3249707A1 (en) 2022-04-27 2023-11-02 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH AN EZH1 AND/OR EZH2 INHIBITOR
EP4522658A1 (de) 2022-05-11 2025-03-19 Daiichi Sankyo Company, Limited Kombination eines für ein tumorantigen spezifischen antikörpers und eines cd47-inhibitors
TW202413430A (zh) 2022-05-12 2024-04-01 日商安斯泰來製藥股份有限公司 抗ｃｄ３７和ｃｄ３的雙特異性抗體
CA3256230A1 (en) 2022-05-24 2023-11-30 Daiichi Sankyo Company, Limited DOSAGE REGIMEN OF AN ANTI-CDH6 ANTIBODY-DRUG CONJUGATE
EP4537842A1 (de) 2022-06-07 2025-04-16 Institute of Science Tokyo Mittel zur prävention oder therapie von amyotropher lateralsklerose, morbus parkinson, huntington, spinocerebellarer ataxie, alterungsdegeneration oder neurologischer erkrankung
CN119836306A (zh) 2022-07-15 2025-04-15 费恩治疗有限公司 与cdcp1结合的抗体药物缀合物和其用途
TW202412859A (zh) 2022-07-28 2024-04-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及雙特異性檢查點抑制劑之組合
TW202417056A (zh) 2022-08-29 2024-05-01 日商第一三共股份有限公司 包含變異Fc區域的抗體藥物結合物
WO2024053574A1 (ja) 2022-09-09 2024-03-14 第一三共株式会社 新規なオリゴ糖、該オリゴ糖の製造中間体、及びそれらの製造方法
TW202421193A (zh) 2022-09-28 2024-06-01 美商英塞特公司 抗ｐｄ－１／ｌａｇ－３雙特異性抗體及其用途
WO2024074498A1 (en) 2022-10-04 2024-04-11 Imcheck Therapeutics Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer
CA3266848A1 (en) 2022-10-19 2024-04-25 Multitude Therapeutics Inc. ANTIBODIES, ANTIBODY-DRUG CONJUGATIONS, PREPARATIONS AND ASSOCIATED USES
AU2023362061A1 (en) 2022-10-19 2025-04-24 Multitude Therapeutics Inc. Antibody-drug conjugate, preparation method therefor and use thereof in resisting tumors
KR20250116683A (ko) 2022-11-25 2025-08-01 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 혈액암에 대한 항체
CN120282803A (zh) 2022-11-30 2025-07-08 第一三共株式会社 抗体-药物缀合物和dnmt抑制剂的组合
WO2024121380A1 (en) 2022-12-08 2024-06-13 Pierre Fabre Medicament Vaccinal composition and adjuvant
EP4634226A1 (de) 2022-12-16 2025-10-22 Pheon Therapeutics Ltd Antikörper gegen cub-domäne enthaltendes protein 1 (cdcp1) und verwendungen davon
IL321045A (en) 2022-12-22 2025-07-01 Chiome Bioscience Inc Anti-human CX3CR1 antibody
JPWO2024158047A1 (de) 2023-01-27 2024-08-02
EP4665354A1 (de) 2023-02-13 2025-12-24 Institut National de la Santé et de la Recherche Médicale Verfahren zur behandlung von erkrankungen im zusammenhang mit eisenüberlastung
EP4669429A1 (de) 2023-02-23 2025-12-31 Imcheck Therapeutics Kombination aus btn3a-aktivierendem antikörper und immun-checkpoint-inhibitoren
CN120858176A (zh) 2023-03-07 2025-10-28 居里研究所 Brca相关癌症中的ung/udg抑制
TW202444423A (zh) 2023-03-14 2024-11-16 日商第一三共股份有限公司 抗cdh6抗體-藥物結合物與vegf抑制劑之組合
WO2024194401A1 (en) 2023-03-21 2024-09-26 Institut Curie Vps4b inhibitor for use in methods for the treatment of hrd cancer
WO2024194402A1 (en) 2023-03-21 2024-09-26 Institut Curie Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
WO2024194673A1 (en) 2023-03-21 2024-09-26 Institut Curie Methods for the treatment of dedifferentiated liposarcoma
CN120917143A (zh) 2023-03-29 2025-11-07 第一三共株式会社 抗cd25抗体及抗cd25抗体-药物偶联物
AU2024248799A1 (en) 2023-03-31 2025-10-23 Daiichi Sankyo Company, Limited Combination of anti-CDH6 antibody-drug conjugate and HIF-2alpha inhibitor
TW202506190A (zh) 2023-04-05 2025-02-16 日商第一三共股份有限公司 利用抗ｍｕｃ１抗體－藥物結合物投予的藥劑低敏感性癌之治療方法
TW202446421A (zh) 2023-04-10 2024-12-01 日商第一三共股份有限公司 抗ｂ７－ｈ３抗體－藥物結合物與ａｔｒ抑制劑或ａｔｍ抑制劑之組合
WO2024213782A1 (en) 2023-04-13 2024-10-17 Institut Curie Methods for the treatment of t-cell acute lymphoblastic leukemia
AU2024251960A1 (en) 2023-04-14 2025-10-23 Incyte Corporation Use of an anti-tgfbetar2/pd-1 bispecific antibody to treat cancer
AU2024257777A1 (en) 2023-04-19 2025-10-30 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and other medicine
TW202506731A (zh) 2023-04-27 2025-02-16 法商感應檢查療法公司 治療多重抗藥性細菌感染之方法
CN121219009A (zh) 2023-05-17 2025-12-26 信达克思制药公司 使用抗集落刺激因子1受体抗体治疗慢性移植物抗宿主病相关的闭塞性细支气管炎综合征的方法
WO2025006737A1 (en) 2023-06-30 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine
WO2025003461A1 (en) 2023-06-30 2025-01-02 Institut National de la Santé et de la Recherche Médicale Methods of treatment of metabolic disorders
WO2025024272A1 (en) 2023-07-23 2025-01-30 Incyte Corporation Methods of treating chronic graft-versus-host disease using an anti-colony stimulating factor 1 receptor antibody
WO2025034542A1 (en) 2023-08-04 2025-02-13 Cornell University Gene signature panel predicting cancer response to immune checkpoint blockade and radiation therapy
US20250136688A1 (en) 2023-08-07 2025-05-01 Janssen Biotech, Inc. Stabilized cd3 antigen binding agents and methods of use thereof
WO2025040820A1 (en) 2023-08-23 2025-02-27 Granular Therapeutics Limited Anti-cd203c antibody conjugates and uses thereof
WO2025056739A1 (en) 2023-09-14 2025-03-20 Medizinische Universität Innsbruck Enhancement of car-t cell efficacy by inhibiting nr2f6
WO2025068180A1 (en) 2023-09-25 2025-04-03 Institut National de la Santé et de la Recherche Médicale Methods of treatment of cancer by targetting cancer - associated fibroblasts
WO2025068157A1 (en) 2023-09-25 2025-04-03 Stromacare COMBINATION OF A βIG-H3 ANTAGONIST AND A PDFG-AA ANTAGONIST FOR THE TREATMENT OF CANCER
WO2025068393A1 (en) 2023-09-27 2025-04-03 Institut Curie Methods for the treatment of fibrotic related diseases
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
TW202523359A (zh) 2023-10-24 2025-06-16 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物與抗pd-1/tim-3雙特異性結合蛋白質之組合
EP4563586A1 (de) 2023-11-28 2025-06-04 Université Paris Cité Neue inhibitoren der lrrk2/pp1-interaktion
WO2025120513A1 (en) 2023-12-05 2025-06-12 Astrazeneca Uk Limited Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor
US20250186450A1 (en) 2023-12-06 2025-06-12 Incyte Corporation COMBINATION THERAPY COMPRISING DGK INHIBITORS and PD-1/PD-L1 INHIBITORS
EP4570262A1 (de) 2023-12-15 2025-06-18 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Chimärer antigenrezeptor gegen den chemokinrezeptor ccr7
WO2025147576A1 (en) 2024-01-06 2025-07-10 Generate Biomedicines, Inc. Anti-il-13 antibodies and methods of use thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025176777A1 (en) 2024-02-20 2025-08-28 Institut Curie Dut inhibition in homologous recombination deficiency cancer
WO2025176860A1 (en) 2024-02-23 2025-08-28 Charité - Universitätsmedizin Berlin Körperschaft des öffentlichen Rechts Dual chimeric antigen receptor construct targeting cea and epcam
FR3159967A1 (fr) 2024-03-06 2025-09-12 Commissariat A L'energie Atomique Et Aux Energies Alternatives Anticorps neutralisant à haute affinité dirigé contre la ricine
WO2025215252A1 (en) 2024-04-12 2025-10-16 Ensocell Ltd Therapeutic agents and methods for targeting myeloid cell subtypes
EP4635980A1 (de) 2024-04-19 2025-10-22 Medigene Immunotherapies GmbH Uni-tags-spezifischer antikörper
WO2025226637A1 (en) 2024-04-22 2025-10-30 Incyte Corporation Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor
WO2025224050A1 (en) 2024-04-22 2025-10-30 Institut National de la Santé et de la Recherche Médicale Methods of treatment of patients suffering from hypomelanosis of ito

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
JPS6033453B2 (ja) * 1978-08-17 1985-08-02 富士電機株式会社 魚切断加工自動化装置
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6014678A (ja) * 1983-07-04 1985-01-25 Taiheiyo Kogyo Kk 電磁弁
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB2188941B (en) * 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
DK554986A (da) * 1986-11-19 1988-07-18 Novo Industri As Human-human hybride cellelinier samt dermed producerede monoklonale cancerantistoffer
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
EP0328404B1 (de) * 1988-02-12 1993-09-29 Btg International Limited Modifizierte Antikörper
KR900700134A (ko) * 1988-04-15 1990-08-11 원본미기재 Il-2 수용체-특이적 키메릭 항체
JP5598363B2 (ja) 2011-02-15 2014-10-01 ソニー株式会社 記憶装置およびその動作方法

Also Published As

Publication number Publication date
ES2440825T3 (es) 2014-05-19
DE98204240T1 (de) 2014-08-21
LU91333I2 (fr) 2007-06-11
KR0178385B1 (ko) 1999-04-01
KR910700350A (ko) 1991-03-14
NL300213I1 (nl) 2006-02-01
JPH04502408A (ja) 1992-05-07
NL300023I1 (nl) 2001-01-02
LU90528I2 (fr) 2000-04-11
EP0451216B2 (de) 2012-06-13
NO2001024I1 (no) 2002-01-21
DE04076438T1 (de) 2014-02-27
NO2005026I1 (no) 2005-12-27
ATE183753T1 (de) 1999-09-15
IL162181A0 (en) 2005-11-20
NO912385D0 (no) 1991-06-19
NL990020I2 (nl) 1999-11-01
JP2007145863A (ja) 2007-06-14
NL300239I1 (nl) 2006-10-02
EP0682040B1 (de) 1999-08-25
EP1477497B1 (de) 2014-11-26
DE19975047I2 (de) 2008-07-03
EP0451216B9 (de) 2012-09-26
DE10075005I2 (de) 2005-06-23
NO2005026I2 (no) 2009-01-19
CZ418691A3 (en) 1993-10-13
SI8912489B (sl) 2000-04-30
YU248989A (en) 1991-10-31
DE122005000057I1 (de) 2009-04-09
YU48700B (sh) 1999-07-28
WO1990007861A1 (en) 1990-07-26
DK199800941A (da) 1998-07-16
JP2828340B2 (ja) 1998-11-25
NL300173I2 (nl) 2006-05-01
DE122005000007I1 (de) 2005-06-30
DE122007000037I1 (de) 2007-08-02
CA2328851A1 (en) 1990-06-28
JP2003245090A (ja) 2003-09-02
CN1057013C (zh) 2000-10-04
DE04076439T1 (de) 2014-12-18
EP1491556A1 (de) 2004-12-29
NO912385L (no) 1991-06-19
DD296964A5 (de) 1991-12-19
LU91272I2 (fr) 2006-10-09
DE10075038I1 (de) 2001-03-01
CA2006865C (en) 2002-08-20
DK119191A (da) 1991-06-19
AU647383B2 (en) 1994-03-24
NO2005005I2 (no) 2009-01-19
EP1491556B1 (de) 2014-04-30
NO2007006I2 (no) 2009-12-07
NL300279I2 (nl) 2007-10-01
DE10075038I2 (de) 2004-08-12
ES2081974T5 (es) 2012-10-29
NL300005I2 (nl) 2000-10-02
NO2006009I2 (no) 2009-12-07
DE68925536T4 (de) 1996-09-19
NZ314793A (en) 1999-11-29
EP0682040A1 (de) 1995-11-15
EP2341080A1 (de) 2011-07-06
NO310473B1 (no) 2001-07-09
IL162181A (en) 2006-04-10
DE68925536T3 (de) 2012-11-22
NO2007006I1 (no) 2007-05-07
NL300426I1 (nl) 2010-02-01
ZA899956B (en) 1990-10-31
LU90411I2 (fr) 1999-09-02
NO2006009I1 (no) 2006-08-07
ES2136760T3 (es) 1999-12-01
HRP920500B1 (en) 1999-12-31
DE122005000007I2 (de) 2009-06-25
DE68929061T2 (de) 2000-04-27
LU91208I2 (fr) 2006-02-28
SI8912489A (sl) 1999-02-28
NL300023I2 (nl) 2001-09-03
ES2081974T3 (es) 1996-03-16
NL300279I1 (nl) 2007-07-02
FI912436A0 (fi) 1991-05-20
PT92758A (pt) 1990-06-29
ES2523810T1 (es) 2014-12-01
ES2492815T3 (es) 2014-10-08
DE122005000057I2 (de) 2009-07-16
NL300213I2 (nl) 2006-07-03
EP0939127A2 (de) 1999-09-01
BG61095B2 (en) 1996-10-31
EP0939127B1 (de) 2014-09-17
DE10075005I1 (de) 2000-11-23
SG78258A1 (en) 2001-02-20
ATE133452T1 (de) 1996-02-15
NL300005I1 (nl) 2000-04-03
LU91627I2 (fr) 2010-02-09
DE68929061D1 (de) 1999-09-30
JPH114694A (ja) 1999-01-12
CA2006865A1 (en) 1990-06-28
NL300239I2 (nl) 2007-03-01
NZ231984A (en) 1997-06-24
LU91139I2 (fr) 2005-04-04
DE122009000071I1 (de) 2010-03-25
NO2009026I1 (no) 2009-11-30
ES2523810T3 (es) 2015-01-12
IE20000331A1 (en) 2001-02-21
NO2001025I2 (no) 2005-03-21
RU2126046C1 (ru) 1999-02-10
NO2001026I2 (no) 2006-11-20
DE68925536D1 (de) 1996-03-07
HRP920500A2 (en) 1996-04-30
CA2328851C (en) 2002-08-13
EP0451216A1 (de) 1991-10-16
DK119191D0 (da) 1991-06-19
CN1043875A (zh) 1990-07-18
DE122006000036I1 (de) 2007-04-19
EP0451216A4 (en) 1992-01-02
DK174317B1 (da) 2002-12-02
PT92758B (pt) 1996-01-31
HU211174A9 (en) 1995-11-28
EP0451216B1 (de) 1996-01-24
AU5153290A (en) 1990-08-13
ES2440825T1 (es) 2014-01-30
LU90676I2 (fr) 2001-02-05
DE68925536T2 (de) 1996-06-20
EP0939127A3 (de) 2004-07-21
JP3604058B2 (ja) 2004-12-22
ES2492815T1 (es) 2014-09-10
FR14C0070I1 (fr) 2014-10-24
JP2009165488A (ja) 2009-07-30
JP2003245091A (ja) 2003-09-02
FI108797B (fi) 2002-03-28
HK1014718A1 (en) 1999-09-30
IL92904A0 (en) 1990-09-17
NL300173I1 (nl) 2005-04-01
NL990020I1 (nl) 1999-09-01
EP1477497A1 (de) 2004-11-17

Similar Documents

Publication Publication Date Title
MC2146A1 (fr) Immunoglogulines chimeriques specifiques de la proteine p55 tac du recepteur de l'il-2

Legal Events

Date Code Title Description
YP Annual fee paid